

# 1 The Beneficial Effects of Herbs in Cardiovascular Diseases

2 Dr. Ipseeta Ray Mohanty<sup>1</sup>

3 <sup>1</sup> MGM Medical College, Navi Mumabi.

4 Received: 29 February 2012 Accepted: 29 March 2012 Published: 11 April 2012

5

---

## 6 **Abstract**

7 The history of medicine dates back perhaps to the origin of human race and since time  
8 immemorial, man has made use of plants for the treatment of disease. Application of various  
9 herbal preparations which are highly effective for curing many diseases seem to have been in  
10 practice as early as 400 BC. The earliest reference to the use of medicinal herbs as a cure for a  
11 disease was found in Ebers Papyrus (2600 BC). In India, references to the curative properties  
12 of herbs in Rig Veda (period estimate between 3500-1800 BC) seem to the earliest records of  
13 use of plants in medicine. However, these references are very brief. More detailed account is  
14 available in the Ayur veda (about 2500 BC), the Indian System of Medicine. After the Vedas,  
15 appeared the two most important works on Indian System of Medicine, the Charak-Samhita  
16 (1000 BC) and Susruta-Samhita (800 BC). The Unani system of medicine further enriched the  
17 Herbal Materia Medica. Sheikh Abu Ali Seena (980-1033 AD), the author of AL QANOON  
18 described various plant medicines in his book Adviya Qalbia (Mamtani and Mamtani,  
19 2005). Herbs have been used in medical treatment and some derivates (aspirin, digitalis) have  
20 become the mainstay of pharmacology. Medicinal plants have been observed to possess  
21 numerous activities with regard to cardiovascular system viz. antiplatelet, hypolipidemic,  
22 anti-inflammatory, hypoglycemic and hypotensive actions. For cardiovascular diseases, herbal  
23 treatments have been used in patients with congestive heart failure, systolic hypertension,  
24 angina pectoris, atherosclerosis, cerebral insufficiency, venous insufficiency, and  
25 arrhythmia. This review compiles herbal medicines that affect the cardiovascular system both  
26 in terms of efficacy and safety as gleaned from the scientific literature that is available. The  
27 purpose of this review article is to critically evaluate the available evidence for

28

---

## 29 **Index terms—**

30 Introduction -The history of medicine dates back perhaps to the origin of human race and since time  
31 immemorial, man has made use of plants for the treatment of disease. Application of various herbal preparations  
32 which are highly effective for curing many diseases seem to have been in practice as early as 400 BC. The earliest  
33 reference to the use of medicinal herbs as a cure for a disease was found in Ebers Papyrus (2600 BC). In India,  
34 references to the curative properties of herbs in Rig Veda (period estimate between 3500-1800 BC) seem to the  
35 earliest records of use of plants in medicine. However, these references are very brief. More detailed account is  
36 available in the Ayur veda (about 2500 BC), the Indian System of Medicine. After the Vedas, appeared the two  
37 most important works on Indian System of Medicine, the Charak-Samhita (1000 BC) and Susruta-Samhita (800  
38 BC). The Unani system of medicine further enriched the Herbal Materia Medica. Sheikh Abu Ali Seena (980-1033  
39 AD), the author of AL QANOON described various plant medicines in his book Adviya Qalbia (Mamtani and  
40 Mamtani, 2005).

41 the role of medicinal herbs in prevention and treatment of cardiovascular diseases. In order to simplify, these  
42 herbs are categorized under the primary diseases they treat. Nonetheless, most herbal medicines have multiple  
43 cardiovascular effects that may frequently overlap. a) Carthamus tinctorius extract Carthamus tinctorius L.

## 5 E) CHUANXIONG-PHTHALIDE

---

44 (safflower), a Chinese herbal medicine is widely used to prevent and treat cardiac disease in clinical practice.  
45 The anti-ischemic effects of a purified extract of *C. tinctorius* (ECT) both in vivo and in vitro was investigated.  
46 For in-vivo studies, an animal model of myocardial ischemic injury induced by left anterior descending coronary  
47 artery occlusion was studied. Pretreatment with ECT (100, 200, 400, 600 mg/kg body wt.) protected the  
48 myocardium from ischemia injury by limiting infarct size and improving cardiac function. For the in vitro  
49 experiment, neonatal rat ventricular myocytes were incubated in H<sub>2</sub>O<sub>2</sub> and the direct cytoprotective effect of  
50 ECT against H<sub>2</sub>O<sub>2</sub> exposure was studied. Pretreatment with 100-400 microg/ml ECT prior to H<sub>2</sub>O<sub>2</sub> exposure  
51 significantly increased cell viability as revealed by 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide  
52 (MTT) assay. ECT significantly reduced H<sub>2</sub>O<sub>2</sub> induced cardiomyocyte apoptosis, as detected by Annexin V  
53 and flow cytometry. Phosphatidylinositol 3 kinase (PI3K) play a role in the signaling cascade involved in ECT  
54 mediated anti-apoptotic effects as the P13K inhibitor (LY294002) blocked the cytoprotective effect conferred by  
55 ECT. It was also observed that the rise in the intracellular level of reactive oxygen species (ROS) as assessed by  
56 2',7'-dichlorofluorescein diacetate (DCFH-DA), was significantly inhibited by ECT treatment. The study provides  
57 evidence that the cardioprotective effect of ECT in myocardial ischemia is mediated via reducing oxidative stress  
58 induced damage and apoptosis (Han et al., 2009).

### 59 1 b) Sini Decoction

60 The cardioprotective activity and mechanism of Sini Decoction (SND) against anti-mitochondrial oxidation injury  
61 caused by myocardial ischemia and reperfusion (I/R) was investigated. Kun ming mice were randomly allocated  
62 to three groups: Control group, I/R Introduction II.

### 63 2 Angina Pectoris

64 Cardiovascular group and SND-treated group. At the end of experiment, hearts of mice were taken out for  
65 estimation of myocardial and mitochondria superoxide dismutase (SOD) activity, myocardium and mitochondrial  
66 malondialdehyde (MDA) content, mitochondrial swelling, lactic acid content of myocardium and Mn SOD mRNA  
67 expression. SND treatment increased the activity of myocardium and mitochondrial SOD (P<0.01), decreased  
68 the content of myocardium and mitochondrial MDA (P<0.01), decreased the lactic Acid content of myocardium,  
69 lighted the swelling of mitochondria (P<0.01) and altered the expression of Mn SOD mRNA (P<0.01). Sini  
70 decoction treatment prevented the mitochondrial oxidation injury caused by myocardial I/R. Cardioprotective  
71 effects may be attributed to increase in the expression of MnSODmRNA (Zhao et al., 2008).

### 72 3 c) Sanwei Tanxiang

73 The effect of Sanwei Tanxiang powder on myocardial pathologic change, myocardium lipid peroxidation and  
74 oxidative stress in an anesthetized rat model of I/R was studied. A rat model of regional myocardial I/R was  
75 established by 30 min occlusion of the left anterior descending coronary artery followed by 40 min reperfusion. The  
76 experimental animals were randomly divided into the sham operation, IR control group, positive control group  
77 and Sanwei Tanxiang treatment groups. The changes in myocardial creatine phosphokinase (CK), antioxidant  
78 enzymes and lipid peroxidation along with the ultrastructural changes were studied. In Sanwei Tanxiang group's  
79 significant myocardial protection, reduction in oxidative stress and improvement in ultrastructural pathological  
80 changes was observed as compared with the I/R model group. The authors conclude that the protective effects  
81 of Sanwei Tanxiang powder on anesthetized rat's hearts against myocardial I/R injury may be related to the  
82 antioxidant activity of Sanwei Tanxiang powder (Kou et al., 2008).

### 83 4 d) Curcumin

84 The protective effect of curcumin against myocardial injury was studied. A rat model of myocardial I/R injury  
85 was established by occluding the left anterior descending branch of coronary artery for 60 min and subsequently  
86 reperfusing for 60 min. Different dose of curcumin (20, 40 mg/kg) were administered by intravenous injection  
87 5 min before the onset of ischemia. The changes in myocardial infarct sizes, the serum CK and lactate  
88 dehydrogenase (LDH), the myocardial lipid peroxidation and free fatty acid (FFA) content, the myocardial  
89 SOD and glutathione peroxidation (GSHPx) activity were estimated. Curcumin (20, 40 mg/kg) reduced the  
90 myocardial infarct sizes, the serum CK and LDH activity. The myocardial lipid peroxidation and FFA content  
91 declined significantly. Upregulation in antioxidant enzyme activity was observed. Curcumin exerted protective  
92 effects on myocardial I/R injury, which may be attributed to inhibition of lipid peroxidation, augmentation of  
93 endogenous antioxidants and improving myocardial metabolism (Cheng et al., 2005).

### 94 5 e) Chuanxiong-phthalide

95 The cardioprotective effect of Chuanxiongpathalide A on endothelial cell injury induced by I/R was studied.  
96 Myocardial injury was induced of a 30-min normothermic global ischemia followed by 60 min reperfusion. The  
97 isolated rat hearts were perfused under constant pressure with Chuanxiong-pathalide A at the concentrations  
98 of 0.012 5 mg/ mL, 0.025 mg/mL and 0.05 mg/mL within 10 min followed by a 10-min washout period before  
99 the induction of I/R. Pretreatment with Chuanxiong-pathalide A produced a reduction in the incidence of

100 reperfusion-induced ventricular fibrillation (VF) and ventricular tachycardia (VT). Pretreatment of the hearts  
101 with high dose of Chuanxiong-pathalide A (0.05 mg/mL) prior to the I/R, reduced the incidence of reperfusion-  
102 induced ventricular fibrillation (VF) and ventricular tachycardia (VT) to 37.5% as compared with non-pretreated  
103 control group ( $P < 0.05$ ). The duration of occurrence of VF and VT in the group pretreated with Chuanxiong-  
104 pathalide A at dosages was significantly shorter than the non-pretreated control group. In the Chuanxiong-  
105 pathalide A treated group increase in coronary flow and significant reduction in the oxidative stress in the  
106 group pretreated with Chuanxiongpathalide A as compared to control group was observed. In addition, enzyme  
107 immunoassays showed decrease in IL-1beta and TXB2/6-Keto-PGF1alpha ratio. Results demonstrated that  
108 chuanxiong-pathalide A pretreatment protected the endothelial function from the injury caused by I/R (Gao et  
109 al., 2005).

## 110 **6 f) Acanthopanax senticosus saponins**

111 The protective effect of Acanthopanax senticosus saponins (ASS) on myocardial I/R injury was investigated. The  
112 myocardial ischemia-reperfusion model was induced by ligating the left anterior descending coronary for 30 min  
113 and thereafter reperfusing for 120 min. The changes in myocardial infarct size, the serum CK and lactate LDH  
114 activity, serum lipid peroxidation content, SOD and GSH-Px activity and plasma endothelin (ET), angiotensin  
115 II (Ang II), prostacycline (PGI2) and thromboxane A2 (TXA2) levels and myocardial FFA content of infarct  
116 and noninfarct area were determined. In rats treated by ASS (in a dosage of 25, 50 and 100 mg/kg i.v. at 30  
117 min after coronary occlusion), the myocardial infarct size was significantly reduced, the serum CK and LDH  
118 activity, the plasma ET, Ang II and TXA2 level and myocardial FFA content declined, while plasma PGI2  
119 level and PGI2/TXA2 was significantly increased. In addition, serum MDA content declined SOD and GSH-  
120 Px activity increased markedly. ASS has protective effect on myocardial I/R injury, which may be due to its  
121 function of improving free radicals and myocardial metabolism, decreasing plasma ET, Ang II and TXA2 levels  
122 and increasing plasma PGI2 level and PGI2/TXA2 ratio (Sui et al., 2004).

## 123 **7 g) Shuangshen tongguan**

124 The study was conducted to observe the effects of Shuangshen tongguan (SSTG) on infarction size and tumor  
125 necrosis factor-alpha (TNF-alpha), intercellular adhesion molecular-1 (ICAM-1) levels in serum during reperfusion  
126 injury of acute myocardial ischemia. To induce myocardial I/R injury, anterior descending branch of coronary  
127 artery was ligated and released. The size and weight of infarction area and the contents of TNFalpha, ICAM-1  
128 in serum were assayed by Nitroblue tetrazolium (N-BT) staining and ELISA respectively. The size and weight  
129 of infarct area and the contents of TNFalpha, ICAM-1 in serum were significantly increased in the control group  
130 compared with the normal group. However, following treated with SSIG a decrease in TNFalpha and ICAM-1  
131 was observed. I/R injury resulted in release of TNF-alpha, ICAM-1. SSTG protected myocardium from I/R  
132 injury by suppressing oversecretion of TNF-alpha and ICAM-1 and reduced the size and weight of infarct area  
133 (Han et al., 2004).

## 134 **8 h) Sasanquasaponin**

135 The effects of sasanquasaponin (SQS), a traditional Chinese herb's in ameliorating I/R injury was assessed.  
136 Further, the possible role of intracellular Clhomeostasis on SQS's protective effects during I/R was also elucidated.  
137 An in vivo experimental ischemia model was induced in mice (weight 27-45 g) using ligation of left anterior  
138 descending coronary artery. In vitro model of isolated perfused heart and isolated cultured ventricular myocytes  
139 were used. The in vivo results showed that SQS inhibited cardiac arrhythmias during I/R. Incidence of  
140 arrhythmias during I/R, including ventricular premature beats and ventricular fibrillation, was significantly  
141 decreased in the SQS-pretreated group ( $P < 0.05$ ). Results in perfused hearts showed that SQS suppressed  
142 the arrhythmias, prevented I/R induced decrease in contract force and promoted the force recovery from  
143 reperfusion. Furthermore, in-vitro intracellular Cl-concentrations ( $[Cl^-]_i$ ) were measured using a fluorescence  
144 method in isolated ventricular myocytes. SQS slightly decreased  $[Cl^-]_i$  in non-hypoxic myocytes and delayed the  
145 hypoxia/reoxygenationinduced increase in  $[Cl^-]_i$  during ischemia and reperfusion ( $P < 0.05$ ). Our results showed  
146 that SQS protected mice against I/R-induced cardiac injury. Modulation of intracellular Cl-homeostasis by SQS  
147 plays a role in its anti-arrhythmia effects during I/R (Lai et al., 2004).

## 148 **9 i) Psidium guajava L, Limonium wrightii and Okinawan 149 medicinal plants**

150 Effects of the aqueous extracts of Psidium guajava L. and Limonium wrightii, (medicinal herbs growing in  
151 Okinawa) at concentrations known to possess antioxidant activity were evaluated in an in vivo model of global  
152 I/R. Results were further compared with those of quercetin and gallic acid, major antioxidative components of P.  
153 guajava L. and L. wrightii, respectively. Both extracts significantly attenuated ischemic contracture during  
154 ischemia and improved myocardial dysfunction after reperfusion. Both plant extracts restored high-energy  
155 phosphates and reduced lipid peroxidation in the reperfused hearts. Quercetin and gallic acid also exerted similar  
156 beneficial effects. These results indicate that P. guajava L. and L. wrightii both have cardioprotective effects

157 against myocardial I/R injury in isolated rat hearts, primarily through their antioxidant actions (Sakanashi,  
158 2003).

### 159 10 j) **Astragalus membranaceus**

160 The effect of components isolated from *Astragalus membranaceus* on myocardial I/R injury was investigated.  
161 Myocardial I/R injury was induced by ligating the left anterior descending coronary artery. The effect of total  
162 saponins, total flavonoids and astragaloside i.v. isolated from *A. membranaceus* on hemodynamics during acute  
163 myocardial ischemia, Na(+)-K(+)-ATPase activity, cAMP and MDA contents in the ischemic myocardium were  
164 assessed. The total saponins, total flavonoids and astragaloside i.v. prevented the decline in cardiac function in rat  
165 heart injured by I/R in vivo, and decreased Na(+)-K(+)-ATPase activity in the ischemic myocardium. Results  
166 demonstrate that the total saponins increased the cAMP content and the total flavonoids decreased the level  
167 of MDA production in the ischemic myocardium. The cardioprotective effects of different components isolated  
168 from *A. membranaceus* on the cardiac function in the process of I/R may be attributed to improving energy  
169 metabolism and antioxidant activity in the ischemic myocardium ??Zhou et al., 2000). k) *Ginkgo biloba* extract  
170 *Ginkgo biloba* leaf extract (GBLE) contains many different flavone glycosides and terpenoides. GBLE showed  
171 significant antioxidant activity, exerted an anti-inflammatory effect on inflammatory cells (by suppressing the  
172 production of active oxygen and nitrogen species), a relaxing effect on vascular walls, an antagonistic action  
173 on platelet-activating factor, an improving effect on blood flow or microcirculation, and a stimulating effect on  
174 neurotransmitters. GBLE inhibited the oxidative decomposition of low-density lipoprotein (LDL), reduced the  
175 cell death in various types of neuropathy, and prevented the oxidative damage to mitochondria. The study using  
176 a model of I-R injury has also demonstrated the protective effect of GBLE on cardiac muscle and its antioxidative  
177 action in vivo. Favorable results have been obtained in double-blind, placebo-controlled, comparative trials of  
178 patients with memory disorders, obstructive arteriosclerosis, and dementia. GBLE shows a very strong scavenging  
179 action on free radicals, and is thus considered to be useful for the treatment of diseases related to the production  
180 of free radicals, such as ischemic heart disease, cerebral infarction, chronic inflammation, and aging ??Yoshikawa  
181 et al., 1999).

182 The cardioprotective efficacy and the total plasma antioxidant activity of a standardized *Ginkgo biloba* L.  
183 extract (GB) (300 mg/kg/day) or complexed with phosphatidylcholine (GB-PC; 1:2 w/w), after a 5 days oral  
184 administration was studied. On the 6th day, the total plasma antioxidant defence was determined by the TRAP  
185 and FRAPS assay. The hearts from all groups of animals were subjected to moderate ischemia (flow reduction  
186 to 1 ml/min for 20 min) and reperfusion (15 ml/min for 30 min). The recovery of left ventricular developed  
187 pressure (LVDP) at the end of reperfusion was 35-40% of the preischemic values in both control and vehicle rats,  
188 50.2% in the GB group and 72.5% in the GB-PC pre-treated animals. CK outflow in the perfusate from the  
189 hearts of GB and GB-PC treated animals were restrained to a different extent vs. controls (by 71% GB-PC; by  
190 22% GB); the rate of prostacyclin (6keto-PGF1 alpha) release was far greater in GB-PC than in GB hearts. In  
191 parallel, the GB extract significantly increased the total antioxidant plasma capacity only when complexed with  
192 phospholipids. This indicated that there was an increase in bioavailability of phenolic antioxidants when suitably  
193 embedded within a lipophilic carrier. The results of this study demonstrated that complexation of *Ginkgo biloba*  
194 with phospholipids provided superior cardioprotection perhaps due to an increased plasma antioxidant activity  
195 (Carini et al., 2003).

196 The cardioprotective effects of EGb 761 on the release of nitric oxide (NO), the concentration of serum  
197 thiobarbituric acid reaction substance (TBARS), the activity of CK and the incidence of ventricular arrhythmias  
198 were investigated in an in vivo model of myocardial I/R injury. The hearts of the Wistar rats were subjected to 30  
199 min of ischemia and 10 min of reperfusion in vivo. Different doses of EGb 761 (25, 50, 100, 200 mg/kg i.p.), SOD,  
200 l-arginine (50 mg/kg i.p.) and nitric oxide synthase inhibitor NG-nitro-l-arginine (NNA, 50 mg/kg i.p.) were  
201 administered to the I/R rats. EGb 761 (100 mg/kg) increased the signal intensity of NOFe2+(DETC)2 complex,  
202 while EGb 761 at 200 mg/kg showed an effect of decreasing the signal intensity of NOFe2+(DETC)2 complex.  
203 EGb 761 inhibited the formation of TBARS, the release of CK, and mitigated the incidence of ventricular  
204 arrhythmias in a dose dependent way. Both l-arginine and SOD increased the signal intensity of NOFe2+(DETC)2  
205 complex and inhibited the formation of TBARS, the leakage of CK and the incidence of ventricular arrhythmia.  
206 In conclusion, EGb 761 demonstrated significant cardioprotective effects by means of adjusting the level of NO  
207 and inhibiting oxygen free radicals induced lipid peroxidation in myocardial I/R injury in vivo ??Shen et al.,  
208 1999).

209 *Ginkgo biloba* extract, a containing kaempferol and quercetin esters, which are potent radical scavengers, was  
210 studied on various models of cardiac ischaemia, both in vitro and in vivo. *Ginkgo biloba* extract showed no  
211 significant effect on the cardiac function in vitro models of I/R injury. However, a significant decrease in the  
212 intensity of ventricular fibrillation during the reperfusion stage was observed. On normal or hypertrophied heart  
213 in vivo, *Ginkgo biloba* extract provided effective protection against the electrocardiographic disorders induced by  
214 ischaemia. On the different models of global or localized ischaemia (followed or not by reperfusion), a decrease  
215 of arrhythmia without change in cardiovascular parameters was regularly noted (Guillon et al., 1986).

216 To assess the cardioprotective and antioxidant effects of therapeutically relevant concentrations of *Ginkgo*  
217 *biloba* extract (EGb 761; 5, 50 or 200 microg/ml), its terpenoid constituents (ginkgolide A; 0.05 microg/ml and  
218 ginkgolide B; 0.05, 0.25 or 0.50 microg/ml), and a terpene-free fraction of EGb 761 (CP 205; 5 or 50 microg/ml),

219 hemodynamic and electron spin resonance (ESR) analyses were performed on isolated ischemic and reperfused rat  
220 hearts. Hearts underwent 10 min of low-flow ischemia, 30 min of noflow global ischemia, and 60 min of reperfusion.  
221 Test substances were added to the perfusion fluid during the last 10 min of control perfusion, low-flow ischemia  
222 and the first 10 min of reperfusion. The study results showed that in vitro exposure of hearts to EGb 761 (5  
223 or 50 microg/ml) or to ginkgolides A and B (both at 0.05 microg/ml), or in vivo pretreatment of the rats with  
224 CP 205 delayed the onset of contracture during ischemia. A significant decline in left ventricular end-diastolic  
225 pressure was observed in the EGb 761, by ginkgolide A, and to a lesser extent by ginkgolide B, or by prior oral  
226 treatment with CP 205 treated hearts. Post-ischemic functional recovery was significantly improved by in vivo  
227 administration of CP 205, by perfusion with 5 microg/ml of EGb 761 or with both terpenoids as compared to  
228 untreated group but in vitro CP 205 was not effective. ESR analyses revealed that free radical concentrations in  
229 coronary effluents were markedly decreased by all treatments, except for the lowest concentration of ginkgolide B.  
230 The findings provide the first evidence that part of the cardioprotection afforded by EGb 761 involves a mechanism  
231 independent of direct free radical-scavenging property. These effects may partly be due to a specific action of its  
232 terpenoid constituents and the flavonoid metabolites that are formed after in vivo administration of the extract.  
233 These may act in a complementary manner to protect against myocardial I/R injury (Liebgott et al., 2000).  
234 1) *Polygonum multiflorum* extract 'Dang-Gui Decoction for Enriching the Blood' (BE), is a traditional Chinese  
235 formulation consisting of *Angelica sinensis* and *Astragalus membranaceus*. It is used for stimulating red blood cell  
236 production as well as enhancing cardiovascular function. In the present study, the myocardial protection afforded  
237 by BE pretreatment against I/R injury in isolated-perfused rat hearts was studied. *Polygonum multiflorum*  
238 extract supplemented BE preparation (BEA) demonstrated a more complete and potent myocardial protection  
239 against IR injury. The results suggest that superior cardioprotective effects demonstrated by BEA may be linked  
240 to its ability to sustain the myocardial glutathione antioxidant status under conditions of I/R-induced oxidative  
241 stress. These beneficial effects may be because of synergistic interaction between the BE and *Polygonum* extract  
242 (Yim et al., 2000).

## 243 11 m) *Panax ginseng*

244 The protective effect of oral administration (one week) of *Panax ginseng* (PG) extract (10 mg/ml in drinking  
245 water; 1.6 g/kg/day) on myocardial post-ischemic damage induced by hyperbaric oxygen (HBO) and on the loss  
246 in functionality of the endothelium in aorta ring preparations was investigated. The hearts from control rats  
247 (no-HBO and no-HBO-PG), and from rats exposed to HBO and to HBO after PG treatment were isolated and  
248 subjected to mild ischemia and then reperfused. Exposure to HBO greatly worsened the post-ischemic damage  
249 in controls. A significant rise of left ventricular end diastolic pressure (LVEDP) and coronary perfusion pressure  
250 (CPP) was observed in the control group. PG significantly attenuated the increase in LVEDP and CPP with  
251 respect to HBO-untreated rats. In HBO control rats the reduction of the vasorelaxant effect of acetylcholine  
252 on norepinephrine precontracted aortic rings, was markedly recovered by PG. A similar trend was observed in  
253 aortic rings challenged with the nitric oxide synthase inhibitor NG-monomethyl-Larginine (56% recovery). These  
254 results strongly indicate that through an antioxidant intervention, PG prevented the myocardial I/R damage  
255 and the impairment of endothelial functionality induced by reactive oxygen species following exposure to HBO.  
256 The antioxidant activity of PG seems to be too weak (0.05-0.5 mg/ml). This suggests the indirect antioxidant  
257 action of the drug (endothelial nitric oxide synthase stimulation) also plays an important role (Maffei Facino et  
258 al., 1999).

## 259 12 n) *Scutellaria baicalensis Georgi*

260 *Scutellaria baicalensis Georgi* is a Chinese herbal medicine used to treat allergic and inflammatory diseases. The  
261 constituent flavones reported to have antioxidant properties may be responsible for the medicinal effects of *S.*  
262 *baicalensis* root. It was investigated whether *S. baicalensis* could confer protection in a cardiomyocyte model of  
263 ischemia and reperfusion. The intracellular fluorescent probes 2',7'dichlorofluorescin diacetate (sensitive to H<sub>2</sub>O<sub>2</sub>  
264 and hydroxyl radicals) and dihydroethidium (sensitive to superoxide) were used to assess intracellular reactive  
265 oxygen species, and propidium iodide was used to assess cell viability in cultured embryonic cardiomyocytes.

266 *S. baicalensis* extract (SbE) significantly attenuated generation of free radicals during transient hypoxia and  
267 during exposure to the mitochondrial site III inhibitor antimycin A, as measured by fluorescent probes. Reduced  
268 oxidative stress was associated with improved survival and function. Cell death after ischemia/reperfusion  
269 decreased significantly in *S. baicalensis* treated cells ( $p < 0.001$ ). After antimycin A exposure, *S. baicalensis*  
270 decreased cell death from 49+/-6 % in untreated to 23+/-4 % in treated cells. Return of contraction occurred  
271 in *S. baicalensis*-treated cells but was not observed in control cells. Studies have revealed that baicalein, a major  
272 flavone component of SbE possess antioxidant property and can directly scavenge superoxide, hydrogen peroxide,  
273 and hydroxyl radicals. Collectively, these findings indicate that SbE and its constituent flavones such as baicalein  
274 can attenuate oxidant stress and protect cells from lethal oxidant damage in an I/R model (Shao et al., 1999).

## 275 13 o) *Crataegus oxyacantha*

276 The effect of water-soluble fraction of *Crataegus* (*Crataegus* extract) was studied on the cardiac mechanical and  
277 metabolic function in the isolated, perfused working rat heart. Ischemia for 15 min was induced by removing

## 15 Q) WITHANIA SOMNIFERA

---

278 afterload pressure, and reperfusion of 20 min was produced by returning it to the original pressure. In the  
279 control (no drug) heart, ischemia decreased mechanical function to the lowest level, which did not recover even  
280 after the end of reperfusion. Crataegus extract (0.01 or 0.05%) was applied to the heart from 5 min before  
281 ischemia through the first 10 min after reperfusion. With the high concentration of Crataegus extract (0.05%)  
282 the mechanical function recovered during reperfusion incompletely without increasing coronary flow, but the low  
283 concentration of Crataegus extract (0.01%) did not. In the heart treated with the high concentration of Crataegus  
284 extract, the reperfusion-induced recovery of the energy metabolism was accelerated. The level of lactate during  
285 ischemia was lower than that in the control heart, though the myocardial levels of free fatty acids during I/R were  
286 not greatly affected. These results demonstrate that Crataegus extract (0.05%) has a cardioprotective effect on  
287 the ischemic-reperfused heart. However, the cardioprotective effect is not accompanied by an increase in coronary  
288 flow ??Nasan et al., 1993).

289 The effect of the pretreatment with the powder of crataegus oxyacantha on the release of LDH during I/R was  
290 studied in an isolated rat heart model. Male Wistar rats were divided into control and crataegus treated group.  
291 For the control group, the standard diet was mixed with a 2% crataegus powder standardized to 2.2% flavonoids.  
292 The investigations started 3 months after commencing the treatment. The hearts were isolated and a retrograde  
293 perfusion was performed at constant pressure according to the technique of Langendorff. The experimental  
294 protocol comprised of 10 min equilibration, according to the technique of Langendorff. The experimental protocol  
295 comprised of 10 min equilibration, 110 min occlusion of the left anterior descending coronary artery, and 30 min  
296 reperfusion. The coronary effluent was sampled for the LDH determination at various time points (5, 30, 90,  
297 120 and 150 min). The LDH activity increased slightly during the ischemia, and markedly as soon as the heart  
298 was reperfused. Crataegus pretreatment resulted in significant decrease in LDH activity. The attenuation of the  
299 LDH release by crataegus pretreatment suggests preservation of the cell membrane and significant myocardial  
300 protection (Al Makdessi et al., 1996).

301 The cardioprotective effects of a standardized extract from leaves with flowers of Crataegus (WS-1442;  
302 content of oligomeric procyandins [OPC]: 18.75%) have been documented in various studies. To elucidate  
303 its cardioprotective mechanism, the active constituents involved in these effects of WS-1442 were identified.  
304 Exhausting partitioning between ethyl acetate/water and successive ultrafiltration of the aqueous layer led to the  
305 quantitative recovery of three fractions, which were tested for their in vitro radical scavenging (RS) and human  
306 neutrophil elastase (HNE) inhibitory activity. The OPCs of Crataegus extracts possess superior antioxidant  
307 activities than flavone derivatives or other constituents. In addition, the oligomeric components are more potent  
308 inhibitors of HNE. Oral administration of 20 mg/kg/d of the OPC-rich fraction to rats afforded comparative  
309 protection against I/R induced pathologies as treatment with 100 mg/kg WS-1442. These observations indicate  
310 that radical scavenging and elastase inhibitory activities could indeed be involved in the observed cardioprotective  
311 effects of WS-1442. The study emphasizes that OPCs are major orally active constituents of WS-1442. Thus,  
312 Crataegus extracts used therapeutically for cardiovascular diseases should be analyzed and standardized for their  
313 OPC-content (Chatterjee et al., 1997).

## 314 14 p) Panax pseudoginseng

315 Trilinolein, a natural plant triacylglycerol, known to have myocardial protective effects was evaluated in  
316 vivo. This study investigated if inhibition of calcium influx and alteration of SOD activity are involved the  
317 myocardial protection mechanism of trilinolein. In isolated cardiomyocytes, pretreatment with 10(-9) M trilinolein  
318 significantly reduced Ca<sup>2+</sup> influx stimulated by hypoxia/normoxia. Pretreatment with 10(-7) M trilinolein (for  
319 15 min) in isolated perfused rat heart subjected to 60 min global hypoxemia without reperfusion significantly  
320 reduced infarct size. SOD-mRNA assay was analysed by Northern blot. Pretreatment with 10(-7) M trilinolein  
321 to in vivo rat heart subjected to 30 min ischaemia and 10 min reperfusion, significantly reduced oxidative  
322 stress. It prevented the rise in SOD-mRNA. These results reconfirm the myocardial protection of trilinolein.  
323 Cardioprotection may be attributed to antioxidant activity and inhibition of Ca<sup>2+</sup> influx ??Chan et al., 1999  
324 ??Chan et al., -2006)).

## 325 15 q) Withania somnifera

326 The cardioprotective effects and mechanisms of *Withania somnifera* (Ws), in the setting of I/R injury were  
327 assessed. Wistar rats were divided into three groups and received orally saline (sham, control I/R) and Ws-50  
328 mg/kg (Ws-I/R), respectively, for 1 month. On the 31st day, in the control IR and Ws-IR group rats, left anterior  
329 descending coronary artery occlusion was undertaken for 45 min followed by 1 h reperfusion. Subsequently, all the  
330 animals were sacrificed for biochemical, immunohistochemical {Bax and Bcl-2 protein}, terminal deoxynucleotidyl  
331 transferase biotin-dUTP nick end labeling (TUNEL) positivity and histopathological studies. Post-ischemic  
332 reperfusion injury resulted in significant cardiac necrosis, apoptosis, and decline in antioxidant status and  
333 elevation in lipid peroxidation in the I/R control group as compared to sham. Ws pretreatment favorably  
334 restored the myocardial oxidantantioxidant balance, exerted marked anti-apoptotic effects {upregulated Bcl-2  
335 (p<0.001) protein, decreased Bax (p<0.01) protein, and attenuated TUNEL positivity (p<0.01)}, and reduced  
336 myocardial damage as evidenced by histopathologic evaluation. It is speculated that the antioxidant and anti-  
337 apoptotic properties of Ws may contribute to the observed cardioprotective effects (Mohanty IR et al., 2008).

338 r) Bacopa monniera Bacopa monniera(Bm), a medicinal herb commonly known as Brahmi is widely used in  
339 the Indian system of medicine. The cardioprotective effects of Bm was studied in the Langendorff model of  
340 myocardial I/R injury. Effect of Bm on cardiomyocyte apoptosis and antioxidant status following I/R injury was  
341 investigated. Forty-eight rats were randomly divided into four groups (12 in each group): sham group (no I/R  
342 injury), Bm control group (orally fed Bm at a dose of 75 mg/kg, for three weeks); I/R control group (subjected to  
343 I/R-induced myocardial injury) and Bm-treated group (same protocol as I/R control group except that rats also  
344 fed Bm). Post-ischaemic reperfusion injury resulted in significant cardiac necrosis, apoptosis, depression of heart  
345 rate, decline in antioxidant status and elevation in lipid peroxidation. Oral administration of Bm per se for three  
346 weeks to healthy rats caused augmentation of myocardial antioxidants, SOD, catalase and glutathione, along with  
347 induction of heat shock protein 72 (HSP72). I/R induced biochemical and histopathological perturbations were  
348 significantly prevented by Bm(75 mg/kg) pre-treatment. Interestingly, Bm also restored the antioxidant network  
349 of the myocardium and reduced myocardial apoptosis, caspase 3 and Bax protein expression. Histopathological  
350 studies and myocardial creatine phosphokinase content further confirmed the cardioprotective effects of Bm (75  
351 mg/kg) in the experimental model of I/R injury. The study provides scientific basis for the putative therapeutic  
352 effect of Bm in ischaemic heart disease (Mohanty IR et al., 2010).

## 353 16 s) **Curcuma longa**

354 The cardioprotective potential of Curcuma longa (Cl) in the I/R model of myocardial infarction was investigated.  
355 Wistar rats were divided into three groups and received saline orally (sham, control I/R group) and Cl 100 mg/kg  
356 (CL-100 treated group) respectively for one month. On the 31st day, rats of the control I/R and Cl treated  
357 groups were subjected to 45 min of occlusion of the LAD coronary artery and were thereafter reperfused for  
358 1 h. I/R resulted in significant cardiac necrosis, depression in left ventricular function, decline in antioxidant  
359 status and elevation in lipid peroxidation in the control I/R group as compared to sham control. Myocardial  
360 injury due to I/R was significantly prevented by Cl treated group. Cl treatment resulted in restoration of the  
361 myocardial antioxidant status and favorable modulation of hemodynamic parameters as compared to control  
362 I/R. Furthermore, I/R-induced lipid peroxidation was significantly inhibited by Cl treatment. The beneficial  
363 cardioprotective effects also translated into the functional recovery of the heart. Cardioprotective effect of Cl may  
364 be attributed to the suppression of oxidative stress and improvement in ventricular function. Histopathological  
365 examination further confirmed the protective effects of Cl on the heart (Mohanty et al., 2004). Further, the  
366 effect of Cl on myocardial apoptosis was studied in the I-R model of myocardial injury. Cl pretreatment reduced  
367 the Bax/Bcl-2 ratio and demonstrated significant anti-apoptotic activity. The antioxidant and anti-apoptotic  
368 properties of Cl may contribute to the cardioprotective effects .III. Congestive Cardiac Failure (Chf) a) *Corydalis*  
369 *yanhusuo*

370 *Corydalis yanhusuo*, a Chinese medicinal plant is reported to possess significant cardioprotective effects. The  
371 main active principle, l-tetrahydropalmatine, is responsible for its pharmacological effects. The protective effects  
372 of *Corydalis yanhusuo* was evaluated in a rat heart failure model. Rats were orally fed with 50, 100, or 200 mg/  
373 kg of ethanolic extract of *Corydalis yanhusuo* daily, from the 7th day after surgery and thereafter subjected to  
374 coronary artery ligation. The cardiac function, plasma atrial natriuretic peptide (ANP), relative heart and lung  
375 weights, infarct size and ventricular dilatation after treatment for 8 weeks were measured. *Corydalis yanhusuo*  
376 treatment led to a significant reduction in infarct size and improvement in cardiac function as demonstrated by  
377 lower LVEDP and elevated +/dp/dt(max). *Corydalis yanhusuo* significantly reduced left ventricular (LV)/body  
378 weight ratio, lung/body weight ratio and inhibited neurohormonal activation. The study concluded that *Corydalis*  
379 *yanhusuo* exerted salutary effects on heart failure induced by myocardial infarction in rats (Wu L et al., 2007).

## 380 17 b) **Shenqi Fuzheng**

381 The effect of Shenqi Fuzheng injection (SFI) on the humoral immunity (IgG IgM IgA), cellular immunity (T-  
382 lymphocyte subsets), SOD activity and plasma viscosity in CHF patients were studied. Sixty patients with CHF,  
383 with heart function of NYHA grade II-IV were randomly divided into two groups. The treated group was treated  
384 with SFI 100 ml, and the control group was treated by 10 mg nitroglycerine injection. To detect the IgG, IgM,  
385 IgA, T-lymphocyte subsets, SOD, lipid peroxidation and plasma viscosity, venous blood from cubital vein was  
386 collected before and after treatment. Results demonstrate that the heart function improved markedly in the  
387 treated group as compared to the control group ( $P < 0.05$ ). The left ventricular ejection fraction (LVEF) and  
388 end systolic volume (ESV) were improved in both group ( $p < 0.05$ ,  $p < 0.01$ ), and the improvement in the treated  
389 group was superior to the control group ( $p < 0.05$ ). In the treated group, the CD4, SOD level and CD4/DC8  
390 ratio increased ( $p < 0.05$ ), whereas lipid peroxidation, IgG and IgM reduced ( $p < 0.05$ ) significantly compared  
391 to the control group. Significant improvement in the plasma viscosity was seen in the treatment group. SFI  
392 improved the immune function of CHF patients. Shenqi Fuzheng injection (SFI) has potential as an adjuvant  
393 therapy in the treatment for CHF (Liu H et al., 2005).

## 394 18 c) **Manshuailing**

395 The clinical effect of manshuailing in patients with CHF was evaluated. A total of 90 heart failure patients were  
396 randomly divided into 2 groups: 45 cases in the routine treatment group (RT) received general therapy including

397 diuretics and digitalis, and 45 cases in the Chinese herbal medicine group (CH) were treated for six weeks with  
398 the above medicine, with additional manshuailing oral liquid for six weeks. The clinical effect was summarized  
399 six weeks after treatment. Total effect rate was 82.2% and 62.2% in CHF and RT group respectively. Compared  
400 with pretreatment, heart function including stroke volume (SV), stroke volume index (SVI), cardiac index (CI),  
401 distance of interventricular septal to mitral valve (EPSS) were all improved significantly in both groups ( $p < 0.05$   
402 or  $p < 0.01$ ). The cardiac function was superior in the CH group as compared to the RT group ( $p < 0.05$   
403 or  $p < 0.01$ ). Manshuailing oral liquid alleviated clinical symptom, decreased EPSS, and improved heart function  
404 (Yang et al., 2003).

405 **19 d) Zhimu and huangqi combination**

406 The efficacy of Zhimu in treating cardiac hypertrophy associated with CHF was evaluated. Mice cardiac  
407 hypertrophy model was established by s.c. Isoproterenol (ISO), 2 times per day for 14 days and heart-weight-  
408 index was measured. Zhimu and Huangqi were given orally alone or jointly for 14 days. Abdominal aorta banding  
409 operation was done in mice and 3 weeks after operation, they were administrated for 2 weeks, and then run-  
410 time (exercise capacity), quiet heart rate, heart rate after ISO and heart-weight-index were measured. Cardiac  
411 hypertrophy model mice were administrated for 12 days, and the mortality and dying time of mice in cold (-20  
412 degrees C) and heat (45 degrees C) stimulative condition were observed. Zhimu could cut down the increasing  
413 of heart rate induced by ISO, decreased significantly heart-weight-index in cardiac hypertrophy mice, reduced  
414 the quiet heart rate and prolonged the run time in abdominal banding model. Zhimu combined with Huangqi  
415 improved the ISO response in abdominal banding model mice, reduce the mortality and delayed dying time of  
416 mice in stimulative condition. Zhimu combined with Huangqi slowed down heart rate, enhanced the reserve force  
417 of the heart, and improved the response capacity of cardiac hypertrophy mice in stimulative condition ??Hu  
418 et al., 2003) .

419 **20 e) Crataegus oxyacantha (aubepine)**

420 Crataegus oxyacantha (Aubepine, Hawthorn), was used by European herbalist in the first century A. D. Until  
421 the 19th century, its true potential for treatment of heart disease was not fully explored. The leaves, flowers, and  
422 berries of hawthorn contain a variety of bioflavonoid-like complexes that appear to be primarily responsible for  
423 the cardiac actions of the plant. Bioflavonoids found in C. oxyacantha include oligomeric procyandins (OPCc),  
424 vitexin, quercetin, and hyperoside. These ingredients are responsible for its beneficial cardiovascular effects (Ju  
425 LY et al., 2005). A placebo controlled, randomized, parallel group, multicentre trial was conducted to assess the  
426 efficacy and safety of a standardized extract of fresh berries of Crataegus oxyacantha L. and monogyna Jacq.  
427 (Crataegisan) in patients with grade NYHA class II cardiac failure. A total of 143 patients (72 men, 71 women,  
428 mean age of 64.8 (8.0 years) were recruited and treated with 3 times 30 drops of the extract ( $n = 69$ ) or placebo ( $n$   
429 = 74) for 8 weeks. The primary endpoint included the evaluation of change in exercise tolerance determined with  
430 bicycle exercise testing; secondary variables included the blood pressure-heart rate product (BHP). Subjective  
431 cardiac symptoms at rest and at higher levels of exertion were assessed by the patient on a categorical rating  
432 scale. The difference between the treatment groups was 8.3 watts in favor of the standardized extract of fresh  
433 Crataegus berries ( $p = 0.045$ ). Although, the results were not statistically significant, changes in BHP at 50 watts  
434 and at comparable maximum load were in favour of Crataegus extract. The subjective assessment of cardiac  
435 symptoms at rest and at higher levels of exertion did not change significantly and the patient and investigator  
436 overall assessment of efficacy were similar for the two groups. The medication was well tolerated and had a high  
437 level of patient acceptability. These results are clinically significant as the symptoms of dyspnoea and fatigue do  
438 not correct until a significantly higher wattage has been reached in the bicycle exercise test. The study concluded  
439 that NYHA II patients showed improvement in their heart failure condition under long term therapy with the  
440 standardized extract of fresh Crataegus berries .

441 **21 f) Berberine**

442 Berberine, is an alkaloid from Hydrastis canadensis L., a Chinese herb Huanglian. It is widely used in traditional  
443 Chinese medicine as an antimicrobial for the treatment of dysentery and infectious diarrhea. Berberine and its  
444 derivatives, tetrahydroberberine and 8oxoberberine have significant beneficial cardiovascular effects. Berberine  
445 has positive inotropic, negative chronotropic, antiarrhythmic, and vasodilator properties. Both derivatives of  
446 berberine have antiarrhythmic activity. Cardiovascular effects of berberine and its derivatives are attributed  
447 to the blockade of K<sup>+</sup> channels (delayed rectifier and K<sup>+</sup>(ATP)) and stimulation of Na<sup>+</sup> -Ca<sup>(2+)</sup> exchanger  
448 and prolongation of the duration of ventricular action potential. Its vasodilator activity has been attributed to  
449 multiple cellular mechanisms. The cardiovascular effects of berberine suggest its possible clinical usefulness in  
450 the treatment of heart failure (Lau et al., 2001).

451 **22 g) Digitalis purpurea**

452 Digoxin has been commonly used to treat patients with CHF, over the past 200 years. William Withering was  
453 able to identify Digitalis purpurea as the essential ingredient in a prescription dispensed by a herbalist, and  
454 systematically proceeded to show its value in patients with cardiac failure (Krikler, 1985). He identified the

455 cardinal symptoms of digitalis intoxication and worked out effective rules for the prescription of an infusion of  
456 digitalis.

457 Use of digitalis for the treatment of patients with CHF and sinus rhythm remains controversial. To ascertain  
458 the proper therapeutic role of digitalis, the published clinical evidence of digitalis was critically appraised. A  
459 search of the English literature from 1960 to 1982 identified 736 articles, of which 16 specifically addressed  
460 the clinical evaluation of digitalis therapy for patients with CHF and sinus rhythm. Only two doubleblind,  
461 placebo-controlled trials provided clinically useful information. One study showed that digoxin therapy could be  
462 withdrawn successfully in elderly patients with stable CHF. The other showed that patients with chronic heart  
463 failure and an S3 gallop benefited from digoxin therapy (Wray et al., 1985; Mulrow et al., 1984).

464 Clinical trials have demonstrated the benefits of the use of digoxin on exercise tolerance, ejection fraction, and  
465 neurohormone production. The Digoxin Investigators Group trial has recently provided strong evidence for the  
466 long-term benefits of digoxin on morbidity for patients with heart failure (Demers et al., 1999).

## 467 **23 h) Red Ginseng**

468 The beneficial effect of red ginseng in CCF was evaluated and compared with Ginseng. Forty-five patients with  
469 class IV cardiac function were divided into three groups of fifteen patients each: group I (digoxin group), group II  
470 (Red Ginseng group) and group III (Red Ginseng plus digoxin group). After treatment, the improvement in the  
471 hemodynamic and biochemical indexes in Red Ginseng group and Red Ginseng plus digoxin group were greater  
472 than those of digoxin group, and group Red Ginseng plus digoxin group was the most significant amongst all.  
473 The results suggested that Red Ginseng and digoxin act synergistically in the treatment of CCF. Red Ginseng is  
474 an effective and safe adjuvant for effective management of CHF (Ding et al., 1995).

## 475 **24 i) Terminalia Arjuna**

476 The beneficial effect of Terminalia Arjuna, an Indian medicinal plant, in CCF was studied in a double blind cross  
477 over study.

478 Terminalia Arjuna was administered to twelve patients with refractory chronic CHF (Class IV NYHA), related  
479 to idiopathic dilated cardiomyopathy (10 patients); previous myocardial infarction (one patient) and peripartum  
480 cardiomyopathy (one patient). Terminalia Arjuna bark extract (500 mg 8hourly) or placebo was administered for  
481 2 weeks each, separated by 2 weeks washout period. The clinical, laboratory and echocardiographic evaluation  
482 was carried out at baseline and at the end of Terminalia Arjuna and placebo therapy. Thereafter, the results  
483 were compared. Terminalia Arjuna, compared to placebo, was associated with improvement in symptoms and  
484 signs of heart failure, improvement in NYHA Class (Class III vs. Class IV), decrease in echo-left ventricular end  
485 diastolic and end systolic volume ( $P < 0.005$ ) indices, increase in left ventricular stroke volume index  $P < 0.05$ )  
486 and increase in left ventricular ejection fractions ( $P < 0.005$ ). Further, on long term evaluation in an open design  
487 Phase II study, participants continued Terminalia Arjuna in fixed dosage (500 mg 8-hourly) in addition to flexible  
488 diuretic, vasodilator and digitalis dosage for 20-28 months (mean 24 months) on outpatient basis. Patients showed  
489 continued improvement in symptoms, signs, effort tolerance and NYHA Class, with improvement in quality of  
490 life (Bharani et al., 1995).

## 491 **25 j) Sini decoction**

492 The study was conducted to investigate the protective effects of Sini decoction (SND) on Adriamycin-induced  
493 heart failure and also elucidate its cardioprotective mechanism. SD rats were randomly divided into three  
494 groups: control group, heart failure model group and SND group. Adriamycin was injected in the rats of  
495 Adriamycin model group and SND group by caudal vein. After injection, the rats in SND group were given  
496 SND (3.75 g/kg) per day, per orally. Three weeks later, protein expressions of Bid and Bcl-xl were detected by  
497 immunohistochemistry; mRNA expression ratio of Bcl-xl/Bcl-xs was detected by RT-PCR and apoptosis rate was  
498 determined by flow cytometry. The protein expression of Bcl-xl and mRNA ratio of Bclxl/Bcl-xs decreased, while  
499 the protein expression of Bid and apoptosis rate significantly increased in the SND treatment group as compared  
500 with the control group. SND could decrease cell apoptosis, increase the protein expression of Bcl-xl, increase  
501 bcl-xl/bcl-xs mRNA ratio and decrease Bid protein expression. Bcl-xl plays an important role in ADR-induced  
502 heart failure in rats. The mechanism of SND cardioprotection may be related to modulation of key regulatory  
503 proteins of apoptosis, Bclxl and Bid (Zhao et al., 2009).

## 504 **26 k) Wenxin Keli**

505 The effect of Wenxin Keli treatment on ISO induced heart failure was studied in rats. Sixty six-week old male  
506 Wistar rats were randomized to six groups. The rats of control group received distilled water every day. Wenxin  
507 Keli (9 mg/kg) was administered for 2 weeks every day. The rats in Wenxin Keli and control group received  
508 two subcutaneous injections (85 mg/kg of ISO, separated by a 24 hour interval). The rats in valsartan and  
509 ISO group received two subcutaneous injections (85 mg/kg) of ISO, and received valsartan 30 mg/kg for 2  
510 weeks every day. Echocardiogram measurement in rats was carried out after 4 weeks and 10 weeks feeding.  
511 In the ISO group, echocardiogram indicated that left ventricular internal diameter at diastolic phase  
512 (LVIDd), left ventricular internal diameter at systolic phase (LVIDs), LV percent fractional shortening (FS) and

513 LV ejection fraction (EF) were reduced. Treatment with valsartan for 4 weeks significantly increased FS and EF  
514 as compared with the ISO group. However, treatment with Wenxin Keli for 10 weeks did not significantly change  
515 the LVIDs, FS, EF compared to the ISO group. 10 weeks of treatment with valsartan and Wenxin Keli resulted  
516 in significant improvement in the hemodynamic parameters: LVEDP, left ventricular systolic pressure (LVSP),  
517 and dp/dt(max). It was concluded that Wenxin Keli significantly improves the ISO induced cardiac dysfunction  
518 (Zhou et al., 2007).

519 IV.

## 520 27 Hypertension a) *Astragalus complanatus*

521 The effects of total flavonoid fraction of *Astragalus complanatus* on blood pressure in conscious spontaneously  
522 hypertensive rats (SHR) and hemodynamics in anesthetized SHR was investigated. It was observed that the  
523 total flavonoid fraction of *Astragalus complanatus* (100, 200 mg/kg) decreased the blood pressure of conscious  
524 SHR significantly (decreasing 7.1%, P < 0.05 and 9.3%, p< 0.01 respectively) and total peripheral resistance  
525 (decreasing 20%, P < 0.05). However, there was no significant change in heart rate and cardiac output. It  
526 was concluded that the total flavonoid fraction of *Astragalus complanatus* possesses significant antihypertensive  
527 effects by virtue of decreasing the total peripheral resistance (Xue et al., 2002).

## 528 28 b) *Allium sativum*

529 *Allium sativum* commonly referred to as garlic, possess a number of beneficial cardioprotective effects. The active  
530 ingredient allicin is responsible for its therapeutic effects. Qidwai et al, 2000 conducted a study to find out whether  
531 individuals with blood pressure (BP) on the lower side consume more garlic in their diets. A questionnaire was  
532 developed and was administered to 101 adult subjects, presenting to the Family Practice Centre of a hospital  
533 in the city of Karachi, Pakistan. It was estimated that average garlic use was 134 grams per case per month.  
534 Subjects with BP on the lower side were found to consume more garlic in their diets (p < 0.05). This study  
535 demonstrates that individuals whose blood pressures (BP) are on the lower side are likely to consume more garlic  
536 in their diets.

537 The effect of garlic on pulmonary pressures in rats subjected to alveolar hypoxia and on vasoconstriction in  
538 isolated pulmonary arterial rings was also studied (Fallon et al., 1998). Garlic gavage (100 mg/kg wt) for 5  
539 days resulted in complete inhibition of acute hypoxic pulmonary vasoconstriction compared with the control  
540 group. These studies document that garlic blocks hypoxic pulmonary hypertension in vivo and demonstrates  
541 a combination of endotheliumdependent and -independent mechanisms responsible for the effect in pulmonary  
542 arterial rings. Meta-analysis concluded that garlic possess significant hypotensive effects only in patients with  
543 increased systolic pressure (Reinhart et al., 2008). Compared to placebo, garlic preparations were found to be  
544 superior in reducing BP in individuals (Ried et al, 2008). The beneficial cardioprotective action of garlic in  
545 essential hypertension (HTN) was studied. The antihypertensive effect of garlic was observed in 20 patients  
546 with HTN receiving garlic pearls preparation for a period of two months ??Dhawan and Jain, 2008). c) Apium  
547 graveolens Apium graveolens, commonly known as celery, according to Chinese theory is known to be effective for  
548 HTN associated with liver disease. In Mainland China, celery was useful in reducing HTN in 14 out of 16 patients.  
549 The juice was mixed with equal amount of honey and about 8 ounces were taken orally three times each day for  
550 up to one week. It significantly reduced systolic and diastolic BP. The difference of BP in human beings before  
551 and after treatment was found to be significant (p<0.05), indicating that seeds of *A. graveolens* possess significant  
552 hypotensive effect. Fresh celery juice can be mixed with vinegar to relieve dizziness and headache and shoulder  
553 pain associated with HTN. It is also effective in HTN associated with pregnancy and climacteric (Gharooni and  
554 Sarkarati, 2000). d) *Artemisia vulgaris* L. *Artemisia vulgaris* L. dried leaves were extracted in distilled water and  
555 chloroform. Two partition fractions from the aqueous extracts and four partition fractions from the chloroform  
556 extracts were tested on male Sprague-Dawley rats using both the in situ mesenteric circulation and the isolated  
557 perfused mesentery. Administration of 10% w/v solutions of water extract fractions FGN 63-1 and FGN 63-2 of  
558 *A. vulgaris* in the isolated perfused rat mesentery model was highly effective in reversing the hypertensive action  
559 induced by norepinephrine with no significant effect on heart rate in either the normotensive or hypertensive  
560 states (Tigno et al, 2000).

## 561 29 e) Ajmaloon

562 Ajmaloon, an herbal drug, was studied in anesthetized rabbits and monkeys for its effect on the arterial BP,  
563 heart rate and baroreceptor-heart rate reflex. Intravenously administered Ajmaloon produced a dosedependent  
564 hypotensive response in both the species without any significant effect on the heart rate. In Ajmaloon treated  
565 animals, loss of tachycardia response to fall in arterial pressure indicated that the drug suppresses normally  
566 existing sympathetic excitatory influence in response to hypotension. Even after intravenous administration  
567 of 100 mg/kg Ajmaloon (a dose much higher than the prescribed highest oral dose for humans), Baroreflex  
568 regulatory heart rate response to hypertension remained intact. Intact baroreflex regulation of arterial BP in  
569 response to hypertension in Ajmaloon treated group suggests that Ajmaloon does not interfere with the normal  
570 BP regulatory mechanism through arterial baroreceptors during hypertension. Study concluded that Ajmaloon  
571 possess significant hypotensive effect ??Fahim et al, 2005).

---

## 572 30 f) *Bidens pilosa* Linn

573 The hypotensive effect of *Bidens pilosa* Linn (Asteraceae) leaves was evaluated in SHR, salt-loading hypertensive  
574 rats (SLHR) and normotensive Wistar rats, using the indirect (tail-cuff) method. Acute changes in urine volume  
575 and urinary excretion of Na<sup>+</sup> and K<sup>+</sup> were also studied. It was found that the hypotensive effect of the extract  
576 was more remarkable in hypertensive than in normotensive rats. Although not statistically significant, the urinary  
577 excretion of Na<sup>+</sup> was decreased by 36% in SHR and the excretion of K<sup>+</sup> increased by 35% in normotensive rats.  
578 These results suggest that the extract has significant hypotensive effect by virtue of its vasodilatory property  
579 (Dimo et al., 1999) g) *Cecropia obtusifolia* (Moraceae)

580 The antihypertensive efficacy of the leaf extract of *Cecropia obtusifolia* was evaluated. *Cecropia obtusifolia*  
581 leaf extract demonstrated significant antihypertensive when administrated intravenously to conscious spontaneous  
582 hypertensive rats. Forty-five minutes after injection, the maximum fall in arterial pressure (-23.5% relative to  
583 pre-injection values) was seen. At the end of the 180 min observation period, recovery was not complete. The  
584 extract was administered to prehypertensive SHR and normotensive rats. The fall in BP was more conspicuous  
585 in the two SHR groups and was not accompanied by changes in cardiac frequency in any group ??Salas et al,  
586 1888).

## 587 31 h) *Crataegus pinnatifida*

588 *Crataegus pinnatifida*, commonly known as hawthorn's decoction has been used in China for treatment of HTN  
589 for thousands of years. The active ingredients that contribute to hawthorn's beneficial effects on heart are  
590 flavonoids and oligomeric procyandins. In experiments with anesthetized rabbits, intravenous administration  
591 of the extract preparation lowered the BP for up to 3 hours (Bensky and Gamble, 1990). Grataegic acid was  
592 identified as the hypotensive principle. Mechanisms of action of *Crataegus* involve a broad-based influence on  
593 the cardiovascular system. The hypotensive activity is mediated via vasorelaxation resulting from nitrous oxide  
594 stimulation, significant antioxidant activity, and a tonic action on cardiac myocytes . i) *Carica papaya* (L.)

595 The hypotensive action of crude ethanolic extract from the unripened fruit of *Carica papaya* was evaluated and  
596 compared with hydralazine. Both hydralazine (200 microg/100 g i. v) and *Carica papaya* extract (20 mg/kg.  
597 i.v) produced a significant depression of mean arterial pressure (MAP) in all groups (p < 0.01 vs controls). The  
598 hypotensive effect of the extract was more profound. It produced about 28% more depression of MAP than  
599 hydralazine in the hypertensive groups. The extract (10 microg/mL) produced relaxation of vascular muscle  
600 tone in vitro studies using isolated rabbit arterial (aorta, renal and vertebral) strips. These effects were however,  
601 attenuated by phentolamine (0.5-1.5 microg/mL). Based on the study results it is concluded that the fruit juice  
602 of *C. papaya* produces significant hypotension attributed to mainly the inhibition of alpha-adrenoceptor activity  
603 (Eno et al, 2000).

## 604 32 j) *Casimiroa edulis*

605 *Casimiroa edulis* seed is reported to possess hypotensive activity. The methanolic extract of *Casimiroa edulis*  
606 contains many active ingredients: synephrine acetonide, N-monomethyl histamine, N,Ndimethyl histamine,  
607 proline, N-methylproline, gammaaminobutyric acid and casimiroedine. These components were isolated. Their  
608 antihypertensive activity was tested in experimental animals. In anesthetized rats, both histamine derivatives  
609 produced transient hypotension mediated via H1-histaminergic receptors and in the case of N,N-dimethyl  
610 histamine, via nitric oxide release. Synephrine acetonide produced transient hypertension and tachycardia,  
611 mediated via alpha and beta-adrenergic receptors, respectively. Nmethylproline, proline and gamma-aminobutyric  
612 acid elicited pronounced and prolonged hypotension. Casimiroedine did not significantly affect on the BP  
613 of anesthetized rats. However, it was capable of lowering blood pressure persistently in anesthetized guinea  
614 pigs. It was concluded that several active components of *C. edulis* are responsible for its hypotensive effects.  
615 Histamine derivatives acting on H1-receptors are responsible for its immediate effect. More prolonged hypotension  
616 is attributed to the mixture of amino acids through an unknown mechanism, as well as by casimiroedine, possibly  
617 by activation of H3-receptors (Magos et al, 1999).

## 618 33 k) *Cecropia lyratiloba*

619 The effect of methanol extract (ME) of *Cecropia lyratiloba* and its flavonoid fraction (FF) on the contractility  
620 of cardiac, vascular and tracheal smooth muscles was evaluated.

621 Adrenaline-induced contractions of the aorta were inhibited by both ME and FF in a concentration-dependent  
622 manner. The flavonoids isolated from FF, namely iso-orientin and a mixture of orientin and isovitexin, were also  
623 tested in the aorta. Results show that this flavonoid is not responsible for the vasorelaxant effects of ME and  
624 FF. The vascular relaxation of FF was abolished in the presence of N(omega)-nitro-L-arginine methyl ester, an  
625 inhibitor of nitric oxide synthase. It was concluded that the endothelium-dependent vasodilation induced by FF  
626 is mediated by the release of nitric oxide (NO). The vascular relaxation demonstrated by ME and FF validate  
627 its traditional use for treatment of arterial hypertension (Ramos et al 2006). l) *Panax ginseng* *Panax ginseng* is  
628 well known to enhance the release of NO from endothelial cells of the rat aorta and to reduce BP in experimental  
629 animals. To further confirm the efficacy of the *Panax ginseng* extract, clinical studies were conducted. The  
630 effects of water extract of Korea red ginseng (KRG) on NO concentration levels in the exhaled breath, BP, and

631 heart rate of human volunteers was studied. It was also investigated whether NO level in exhaled breath was  
632 increased by KRG extract, and if any correlation between BP and heart rate. A single administration of KRG  
633 water extract (500 mg/50 kg) increased NO levels in exhaled breath, and concomitantly decreased mean blood  
634 pressure and heart rate of twelve healthy, non-smoking male volunteers. The correlation value between NO levels  
635 and heart rate ( $r = 0.94$ ), and the correlation value between NO levels and heart rate ( $r = 0.84$ ) were found to  
636 be significant ( $P < 0.01$ ). Linear regression analysis shows the clear conversed correlation between NO levels  
637 and BP as well as heart rate. The results support the claim that KRG may be useful for the treatment of HTN  
638 and pulmonary vascular obstruction (Han et al, 2005) Han et al, 1998, evaluated the changes in diurnal blood  
639 pressure pattern (24 hour ambulatory blood pressure monitoring) after 8 weeks of red ginseng medication (4.5  
640 g/day). Study was conducted among 26 subjects with essential hypertension. Their 24 hour mean systolic blood  
641 pressure decreased significantly ( $p = 0.03$ ) while diastolic blood pressure showed only a slight decline ( $p = 0.17$ ).  
642 The decrease in pressures were observed at daytime (8 A.M.-6 P.M.) and dawn (5 A.M.-7 A.M.). 8 subjects were  
643 probably of white coat hypertension, as no significant change in BP was observed. Based on the results, it was  
644 concluded that red ginseng might be useful as a relatively safe medication adjuvant to current antihypertensive  
645 medications.

### 646 34 m) Ginkgo biloba

647 The acute effect of ginkgo (Ginkgo biloba L.) ethanolic extracts on arterial BP, and heart rate in anesthetized  
648 normotensive rats was examined and compared. The left carotid artery was used for the measurement of arterial  
649 BP. The intravenous administration of the extracts produced a statistically significant dose-dependent and  
650 reversible hypotensive and bradycardic effects (Brankovic et al, 2011). The effects of Ginkgo biloba extract  
651 (GBE) on the development of hypertension, platelet activation and renal dysfunction in deoxycorticosterone  
652 acetate (DOCA)-salt hypertensive rats was also studied (Umegaki et al, 2000). Both DOCA-salt hypertensive  
653 rats and normotensive rats were fed a 2% GBE diet for 20 days. The tail-cuff and telemetry methods were used  
654 for the measurement of BP. Rats fed a 2% GBE diet did not develop significant hypertension. In addition, an  
655 increase in heart weight, an indicator of sustained high BP, was inhibited significantly by feeding of the GBE diet.  
656 Feeding of the GBE diet also decreased 5hydroxytryptamine content in platelets, a marker of platelet activation  
657 in vivo associated with hypertension. The telemetry study demonstrated that BP and heart rate showed a clear  
658 circadian rhythm and the antihypertensive effect of GBE was prominent in the daytime, a resting period for rats.  
659 This anti-hypertensive effect of GBE was not detected in normotensive rats (Umegaki et al, 2000).

### 660 35 n) Guazuma ulmifolia

661 The hypotensive effect of procyanidin fraction (PCF) obtained from acetone extract of Guazuma ulmifolia bark  
662 was studied. 10 mg/kg PCF dose was orally administered to sugar-fed hypertensive rats. PCF significantly  
663 decreased both the systolic arterial pressure and the heart rate, whereas the same doses administered intravenously  
664 induced arterial hypotension. Hypotensive effect was attenuated by NG-nitro-Larginine methylester (L-NAME)  
665 pretreatment. The PCF reduced the contraction induced by norepinephrine ( $1 \times 10^{-7}$  M) in isolated aortic  
666 rings of normotensive and sugar-fed hypertensive rats. Vascular endothelium removal or L-NAME (30 microM)  
667 pretreatment inhibited the relaxant activity of PCF. Procyanidin oligomers consisting mainly of tetramers and  
668 trimers are the active ingredients of PCF responsible for its hypotensice effects. Guazuma ulmifolia bark  
669 possesses long-lasting antihypertensive and vasorelaxing properties. These beneficial effects can be linked to  
670 the endothelium related factors; involving nitric oxide (Magos et al, 2008).

### 671 36 o) Hibiscus sabdariffa

672 The antihypertensive effect of the plant extract of Hibiscus sabdariffa was evaluated. It was observed that in  
673 experimentally induced hypertensive rats, an intravenous administration of 20 mg/kg aqueous extract of dry  
674 H. sabdariffa calyx produced a significant fall in the BP. The hypotensive effects of the crude extract of H.  
675 sabdariffa may be mediated through direct vasorelaxant effects of acetylcholine and histamine. Earlier report  
676 showed that the petal crude extract of same plant produced a direct relaxant effect on the aortic smooth muscle  
677 of rats (Herrera-Arellano et al., 2004). The chronic administration of aqueous extract of HS has been reported  
678 to reverse cardiac hypertrophy in reno-vascular hypertensive rats. A clinical trial of the plant extract has shown  
679 reliable evidence of antihypertensive effect. A standardized dose of H. sabdariffa (9.6 mg per day) given to 39  
680 patients and captopril, 50 mg per day, given to the same number of patients did not show significant difference  
681 relative to hypotensive effects, antihypertensive effectiveness and tolerability ??Odigie et al., 2003).

### 682 37 p) Herniaria glabra

683 The antihypertensive effects of Herniaria glabra saponins was studied and compared with that of furosemide.  
684 Spontaneously hypertensive rats were treated with Herniaria glabra saponins at a dosage of 200mg/Kg of body  
685 weight. Treatment with Herniaria glabra saponins led to significant decline in both systolic and diastolic blood  
686 pressures after 1 month. However, no significant change in heart rate was observed. It was concluded that H.  
687 glabra saponins lowered blood pressure by multifactorial mechanism (Rhiouani et al, 2001). q) Olea. africana  
688 (Oleaceae)

689 The effects of crude extract of the root and stem of *Olea africana* on MAP and heart rate in normo and  
690 hypertensive rats was studied in experimental rats. An immediate and dose dependent fall in MAP and heart  
691 rate in anaesthetised normotensive rats was produced by intravenous administration of aqueous and ethanolic  
692 extracts of *Olea Africana*. The efficacy of the aqueous extract was more superior to the ethanolic extract. Orally  
693 administered aqueous extract produced lowering of MAP and HR in DOCA-salt hypertensive rats (Osim et al,  
694 1999). r) *Rauwolfia serpentina* Reserpine, was the purified alkaloid of *Rauwolfia serpentina*. It was the first potent  
695 drug widely used for the long-term treatment of hypertension. In Europe, Georg Eberhard Rumpf first reported  
696 about *rauwolfia* in his *Herbarium amboinense*, 1755. The first modern paper about therapeutic applications of  
697 the whole root of *rauwolfia* was published in 1931 in the Indian Medical Journal by Sen and Bose, and many  
698 papers dealing with botanics, chemistry and pharmacology then appeared in Indian and European periodics. In  
699 1949, Vakil published the first report of the antihypertensive effect of *rauwolfia* in the British Heart Journal. In  
700 the Ciba laboratories in Basel, Switzerland, Mueller, Schlittler and Bein analyzed various *rauwolfia* alkaloids and  
701 published in 1952 the first complete report about their chemistry and pharmacology. In the same year, reserpine  
702 was introduced under the name Serpasil for the treatment of hypertension, tachycardia and thyreotoxicosis (Jerie  
703 et al, 2007).

704 In a carefully controlled series of 39 severe cases of hypertension (38 with essential hypertension and 1 with  
705 nephritic hypertension) treated for 6 to 20 months with *rauwolfia* preparations, a fall in BP in 67% of cases  
706 was observed. In most cases there was a proportionate fall in both systolic and diastolic BP, but in several the  
707 fall in the diastolic appeared to be relatively greater than in the systolic. The fall was slight (10-20 mm. Hg  
708 diastolic) in 21 % but appreciable or marked in 46% (greater than 20 mm. Hg diastolic), and in four patients the  
709 diastolic BP fell to below 100 mm. Hg (S. Locket, 1955). s) *Terminalia superba* *Terminalia superba*, is used in  
710 traditional Cameroonian medicine as an antihypertensive remedy. Tom et al., 2010 investigated the hypotensive  
711 efficacy of the aqueous extract of *Terminalia superba*. Rats were orally administered 10% D-glucose for 3 weeks  
712 to induce hypertension. The antihypertensive effects were studied after oral administration of the extract (50  
713 and 100 mg/kg/day) or nifedipine (10 mg/kg/day) for 3 weeks. BP and heart rate were measured along with  
714 the antioxidant parameters in the heart, aorta, liver and kidney at the end of the experiment. Intravenous  
715 administration of the aqueous extract of *Terminalia superba* induced a significant hypotensive response without  
716 any significant change in HR. The oral administration of the extract significantly prevented the rise in BP  
717 in glucose-hypertensive rats. Treatment with plant extract resulted in withdrawal of sympathetic tone and an  
718 improvement in the antioxidant status as it significantly reduced the oxidative stress associated with hypertension.  
719 The present study demonstrates that the aqueous extract of the stem bark of *Terminalia superba* exhibits  
720 significant hypotensive effects that are, at least in part, related to a withdrawal of sympathetic tone and to an  
721 improvement of the antioxidant status (Tom et al., 2010). t) Xingnao Qingxuan Zhou et al., 1999 studied the effect  
722 of Xingnao Qingxuan capsules (XQC) in decreasing BP of normal and anesthetized cats. Oral administration of  
723 XQC, 2.8 g/kg produced a decrease in BP of normal cats. XQC 1.4, 2.8 and 5.6 g/kg once a day for 14 days,  
724 produced a dose-dependent reduction of BP in SHR. Although after 3-4 days of administration the BP returned  
725 to the baseline values but the change was not statistically significant. With oral administration of 2.8 and 5.6  
726 g/kg XQC, the incubation period of eyeball tremor induced by chloroform by dropping into the ear was prolonged  
727 by 14.4% and 13.0%, and the keeping time shortened by about 33.3% and 23.3% respectively. Brain basic arterial  
728 spasm induced by KCl or 5-HT in dog was relaxed significantly by XQC in vitro experiment. Results demonstrate  
729 that XQC reduces blood pressure resisting dizziness (Zhou et al., 1999).

### 730 38 u) *Stephania tetrandra* S Moore

731 The hypotensive effect of the extract of *Radix Stephaniae Tetrandrae* (RST), the root of a Chinese hero *Stephania*  
732 *tetrandra* S Moore was evaluated experimentally. Results were compared to those of tetrandrine (Tet), active  
733 component of RST (Wong et al., 2000). The RST extract inhibited Ca<sup>2+</sup> influx into the myocyte and reduced  
734 protein release during reperfusion. RST extract suppressed elevation of arterial blood pressure in DOCA-salt  
735 hypertensive rats. The results suggest that the efficacy of the RST extract cannot be accounted for by Tet  
736 alone. Some of the effects may be due to an interaction between the components of the extract. The RST  
737 extract produced similar hypotensive effects as verapamil, a prototype Ca<sup>2+</sup> channel antagonist widely used  
738 in the treatment of hypertension. v) *Solanum sisymbriifolium* S. *sisymbriifolium* Lam., root, a perennial herb,  
739 has been used as a traditional medicine in Paraguay. It possesses diuretic and antihypertensive properties. The  
740 hypotensive effect of the crude hydroalcoholic extract from root was investigated both in normotensive and  
741 hypertensive rats. The intravenous administration of the extract (50 and 100 mg/kg) produced a significant  
742 decrease in BP in anesthetized DOCA hypertensive rats. Oral administration of the extract (10, 50, 100, and  
743 250 mg/kg) produced a dose-dependent hypotensive effect in conscious hypertensive animals. In anesthetized  
744 normotensive rats, the extract (50 and 100 mg/kg, i.v) induced hypotension in a dose-dependent manner. When  
745 administered orally (10, 50, 100, 250, 500, and 1000 mg/kg) to conscious normotensive rats, no significant effect  
746 on BP was produced by the extract. In another study, the active ingredient nuatigenosido was isolated from the  
747 extract. Nuatigenosido at 100 g/kg and 1 mg/kg i.v lowered BP in rats and at 10<sup>−6</sup> and 10<sup>−5</sup> M augmented the  
748 contractile force in the right atrium of a bullfrog. Nuatigenosido at 10<sup>−7</sup> M increased the overshoot amplitude  
749 in frog atrial myocytes, the action potential duration was shortened, the calcium current was increased, and the  
750 delayed outward potassium current was increased. The study concluded that nuatigenosido may play an important

751 role in the therapeutic effects of this herb (Ibarrola et al., 2003). w) *Uncaria rhynchophylla* U. *rhynchophylla* has  
752 been used in traditional oriental medicine to lower BP and relieve various neurological symptoms. The indole  
753 alkaloid called hirsutine acts on calcium channels and is responsible for its hypotensive activity. The effects  
754 of hirsutine on cytosolic  $Ca^{2+}$  level ( $[Ca^{2+}]_{cyt}$ ) were studied by using fura-2- $Ca^{2+}$  fluorescence in smooth  
755 muscle of the isolated rat aorta. Noradrenaline and high  $K^{+}$  solution produced a sustained increase in  $[Ca^{2+}]_{cyt}$ .  
756 Application of hirsutine after the increases in  $[Ca^{2+}]_{cyt}$  induced by noradrenaline and high  $K^{+}$  notably  
757 decreased  $[Ca^{2+}]_{cyt}$ . Results suggest that hirsutine inhibits  $Ca^{2+}$  influx through voltage-dependent  $Ca^{2+}$   
758 channel. Furthermore, hirsutine had profound effect on intracellular  $Ca^{2+}$  stores. It significantly reduced the  
759 caffeine-induced contraction under the  $Ca^{2+}$ -free nutrient condition in the rat aorta. During  $Ca^{2+}$  loading when  
760 hirsutine was added it augmented the contractile response to caffeine. It was concluded that hirsutine reduces  
761 intracellular  $Ca^{2+}$  level through its effect on the  $Ca^{2+}$  store as well as through its effect on the voltage-dependent  
762  $Ca^{2+}$  channel. In another study, the methanolic extract of the hooks of an *Uncaria* species was found to have  
763 a potent and long-lasting hypotensive effect in rats. Further studies of the extract resulted in the isolation of  
764 3-indole alkaloid, glycoside, cadambine, dihydrocadambine, and isodihydrocadambine. The active ingredients  
765 dihydrocadambine, and isodihydrocadambine were found to possess significant hypotensive property, whereas  
766 cadambine was inactive (Endo et al., 1983).

767 x) *Zingiber officinale* *Zingiber officinale* (Zo.Cr), commonly known as Ginger is used in Asian cooking. It  
768 is known to improve the blood circulation. In anesthetized rats, the crude extract of Zo.Cr induced a dose-  
769 dependent (0.3-3 mg/kg) fall in the arterial BP. In guinea pig paired atria, Zo.Cr exhibited a cardiodepressant  
770 activity on the rate and force of spontaneous contractions. In rabbit thoracic aorta preparation, Zo.Cr inhibited  
771 the phenyl ephrine-induced vascular contraction at a dose ten times higher than that required against  $K^{+}$  (80  
772 mM) induced contraction. Similar to the effect of verapamil, Zo.Cr shifted the  $Ca^{2+}$  dose-response curves to the  
773 right, confirming the  $Ca^{2+}$  channel-blocking activity. The results suggest that the hypotensive effect of Zo.Cr  
774 is mediated via blockade of voltage-dependent calcium channels. Chronic administration of Pet ether extract  
775 (PE) (50 mg/kg/day; po), toluene fraction (10 mg/kg/day; po) of ginger rhizome, and Korean ginseng extract  
776 (KGE) (30 mg/kg/day; po) significantly reduced the BP in DOCA salt-induced hypertensive rats. The PE  
777 (50 mg/kg/day; po) and KGE (30 mg/kg/day; po) produced significant hypotensive effects in fructose-induced  
778 hypertensive rats. It was also speculated that the hypotensive mechanism of action may partly be attributed to  
779 serotonin antagonism. Few clinical trials using low dose Zo.Cr have been undertaken with inconclusive results  
780 (Nicoll and Henein, 2009). y) *Zygophyllum coccineum* Gibbons and Oriowo, 2001, studied the effects of an  
781 aqueous extract of *Zygophyllum coccineum* L. on rat BP and on the mesenteric vascular bed. The extract dose-  
782 dependently reduced BP and heart rate in normotensive and spontaneously SHRs. It also reduced BP in pithed  
783 SHRs. In vitro, the extract had no effect on basal perfusion pressure of the mesenteric vascular bed. However,  
784 when the perfusion pressure was raised with noradrenaline or potassium chloride, the extract produced a dose-  
785 dependent reduction in perfusion pressure. It was concluded that extracts of *Z. coccineum* possess significant  
786 hypotensive activity which may be attributed to membrane hyperpolarization (Gibbons and Oriowo, 2001).

## 787 **39 z) Withania somnifera and Terminalia Arjuna combination**

788 In Ayurveda, medicinal plants, *Withania somnifera* (Ws) and *Terminalia Arjuna* (Arjuna) have been described  
789 to be beneficial for cardiac ailments. Ashwagandha is categorised as Rasayana, known to promote health  
790 and longevity and Arjuna primarily for treatment of heart ailments (coronary artery disease, heart failure,  
791 hypercholesterolemia, anginal pain and can be considered as a useful drug for coronary artery disease,  
792 hypertension and ischemic cardiomyopathy). The present investigation assessed the effects of Ws and Arjuna  
793 individually and as a combination on maximum velocity, average absolute and relative power, balance, maximum  
794 oxygen consumption ( $VO_2$  max) and blood pressure in humans. Ws and Arjuna were administered in the form  
795 of capsules (dosage 500mg/day). Thirty participants were assigned to experimental group of which 10 received  
796 standardized root extracts of Ws, 10 received standardized bark extract of Arjuna and the rest of the 10 received  
797 standardized root extract of both Ws and Arjuna. Ten participants received placebo (capsules filled with flour).  
798 All the subjects continued the regimen for 8 weeks. All variables were assessed before and after the course of drug  
799 administration. The results showed that Ws increased velocity, power and  $VO_2$  max whereas Arjuna increased  
800  $VO_2$  max and lowered resting systolic blood pressure. When given in combination, the improvement was seen  
801 in all parameters except diastolic blood pressure. Ws were found to be useful for treating generalized weakness,  
802 improving speed and lower limb muscular strength and neuro-muscular co-ordination. Arjuna was found to be  
803 beneficial in improving cardiovascular endurance and lowering systolic blood pressure (Sandhu et al., 2010).

804 IV.

## 805 **40 Hypolipidemics a) Bougainvillea spectabilis**

806 The active ingredient, D-pinitol (3-O-methylchiroinositol), of the traditional antidiabetic plant, *Bougainvillea*  
807 *spectabilis*, has significant antidiabetic effects. This study was undertaken to evaluate the effect of D-pinitol on  
808 lipids and lipoproteins in streptozotocin (STZ)-induced diabetic Wistar rats. Type II diabetic was induced by a  
809 single intraperitoneal injection of 40 mg/kg STZ. In diabetic rats, a significant increase in blood glucose, total  
810 cholesterol, triglycerides, free fatty acids, phospholipids in the liver, kidney, heart, and brain was observed. In

811 diabetic rats, a significant increase in the levels of low-density lipoprotein (LDL), very low-density lipoprotein  
812 (VLDL) cholesterol and a decrease in the high-density lipoprotein (HDL) were seen in diabetic rats. Oral  
813 administration of D-pinitol to STZ-induced diabetic rats showed significant ( $p < 0.05$ ) decrease in the levels  
814 of blood glucose and total cholesterol, triglycerides, free fatty acids, and phospholipids in serum, liver, kidney,  
815 heart, and brain. Treatment with Dpinitol significantly ( $p < 0.05$ ) lowered LDL and VLDL cholesterol levels and  
816 significantly ( $p < 0.05$ ) increased HDL cholesterol levels in the serum of diabetic rats. Thus, the present study  
817 clearly demonstrates the antihyperlipidemic effect of D-pinitol in STZ-induced type II diabetic rats (Geethan et  
818 al., 2008).

## 819 **41 b) Daming capsule**

820 The hypolipidemic effect of darning as well as the mechanism of its hypolipidemic effect was elucidated. The  
821 expression of connexin43 in the myocardium before and after using the capsule was studied. Forty Wistar rats  
822 were randomly divided into 5 groups: control group, hyperlipemia model group and Daming capsule treatment  
823 (200, 100, 50 mg/kg) groups. The indexes of total cholesterol (TC), TG, LDL, HDL and non-esterified free fatty  
824 acid (NEFA) in the serum were measured via vena caudalis. The myocardial total RNA was extracted by Trizol  
825 method.

826 RT-PCR, immunostaining and microconfoul was used to study the expression of connexin 43. The  
827 concentrations of TC, TG, LDL and NEFA in hyperlipemic serum were significantly increased ( $P < 0.05$ ), while  
828 that of HDL decreased ( $P < 0.05$ ). Daming capsule treatment decreased the concentration of the preceding four  
829 indexes. The concentration of HDL was increased up to baseline levels. No significant difference was found in  
830 the ECG of the three groups. The mRNA expressions of connexin43 in hyperlipemia group was weakened ( $P$   
831  $< 0.05$ ), while that of the drug group was enhanced ( $P < 0.05$ ) as compared with the normal group. The study  
832 demonstrates that changes in Cx43is responsible for the hypolipidemic activity of Darning capsule (Xing et al.,  
833 2007). c) 'Trikatu' 'Trikatu' is an indigenous preparation containing Piper longum (fruit), Piper nigrum (fruit)  
834 and Zingiber officinale (rhizome) dry powder. To ascertain its efficacy as a hypolipidaemic agent, Trikatu' was fed  
835 to normal and cholesterol fed male Rattus norvegicus. Its effects on body weight, blood and tissue (aortic, cardiac  
836 and hepatic) lipids—total, free and esterified cholesterol, LDL and HDL cholesterol, TG and phospholipids-and  
837 the atherogenic index were measured. 'Trikatu' reduced triglycerides and LDL cholesterol and increased HDL  
838 cholesterol. Hence Trikatu' can reduce the risk of hyperlipidaemia and atherosclerosis. It was concluded that  
839 'Trikatu' possess significant hypolipidaemic activity and it reduces the atherosclerosis associated with a high fat  
840 diet (Sivakumar and Sivakumar, 2004). d) Garlic ??ordia et al., 1981 were the first to evaluate the hypolipidemic  
841 activity of garlic. A clinical study using garlic was conducted on two groups of individuals.

842 Group A consisted of 20 healthy volunteers who were fed garlic for 6 months and then followed for another 2  
843 months without garlic. Administration of garlic significantly lowered the serum cholesterol and TG while raising  
844 the HDL. Group B consisted of 62 patients with coronary heart disease with elevated serum cholesterol. They  
845 were randomly divided into two subgroups: B1 was fed garlic for 10 months while B2 served as a control. Results  
846 demonstrated that garlic intake decreased the serum cholesterol ( $p < 0.05$ ), TG ( $p < 0.05$ ) LDL ( $p < 0.05$ ) while  
847 increasing the HDL fraction ( $p < 0.001$ ). These changes in lipid profile were statistically significant at the end of 8  
848 months and persisted for the next 2 months of follow-up. This study demonstrates that the essential oil of garlic  
849 has distinct hypolipidemic action in both healthy individuals and patients of coronary heart disease ??Bordia et  
850 al., 1981). Hyperlipidemia and oxidative stress may be involved in coronary heart disease and the progression of  
851 renal damage in Nephrotic syndrome (NS) patients. Studies have documented that hypolipidemic and antioxidant  
852 properties of Garlic may be responsible for its beneficial effects. In the present study the effect of a 2% garlic diet  
853 on acute and chronic experimental NS induced by puromycin aminonucleoside (PAN) was studied. Acute NS was  
854 induced by a single injection of PAN to rats and sacrificed after 10 days. Chronic NS was induced by repeated  
855 injections of PAN to rats and sacrificed 84 days after the first injection. Results indicate that garlic treatment was  
856 unable to modify proteinuria in either acute or chronic NS, and hypercholesterolemia and hypertriglyceridemia  
857 in acute NS. However, garlic intake diminished significantly total-cholesterol, LDLcholesterol and TG, but not  
858 HDL-cholesterol in chronic NS. Garlic significantly prevented the oxidative stress (in vivo renal H2O2 production  
859 and the diminished renal Cu, Zn-SOD and catalase activities in acute NS). Results demonstrate that garlic  
860 treatment ameliorates hyperlipidemia and renal damage in chronic NS (Pedraza-Chaverri et al., 2000).

## 861 **42 e) Red ginseng**

862 Red ginseng is the steamed and dried root of Panax ginseng. Active ingredient (ginseng saponin) isolated from  
863 red ginseng was studied in a cyclophosphamide (CPM)-induced hyperlipidemia model in fasted rabbits. In this  
864 model, chylomicrons and VLDL accumulation occurs as a result of release of lipoprotein lipase from the heart.  
865 Oral administration of ginseng saponins at a dose of 0.01 g/kg for 4 weeks reversed the increase in serum TG and  
866 concomitant increase in cholesterol produced by CPM treatment. In addition, ginseng saponins treatment led  
867 to a recovery in post heparin plasma lipoprotein lipase activity and heparin-releasable heart lipoprotein lipase  
868 activity, which were markedly reduced by CPM treatment. In rats given 15% glycerol/15% fructose solution,  
869 postheparin plasma lipoprotein lipase activity declined to two third of normal rats, whereas ginseng saponins  
870 reversed it to normal levels. This study demonstrates that ginseng saponins sustained lipoprotein lipase activity

871 at a normal level. It maintained the lipoprotein lipase activity and produced significant hypolipidemic activity  
872 (Inoue et al., 1999). f) *Tinospora cordifolia* *Tinospora cordifolia* is an indigenous plant widely used in Ayurvedic  
873 medicine in India. The present study was undertaken to evaluate the hypolipidaemic effect of an aqueous extract  
874 of *Tinospora cordifolia* roots. A significant reduction in serum and tissue cholesterol, phospholipids and free fatty  
875 acids was seen in alloxan diabetic rats after administration of the extract of *T. cordifolia* roots (2.5 and 5.0 g/kg  
876 body weight) for 6 weeks. The root extract at a dose of 5.0 g/kg body weight showed significant hypolipidaemic  
877 effect (Stanely Mainzen et al., 1999).

### 878 43 g) *T. arjuna*

879 The effect of orally administered indigenous drugs *Terminalia arjuna*, *T. belerica* and *T. chebula* were investigated  
880 on experimental atherosclerosis. Rabbits were fed a cholesterol-rich diet to induce atherosclerosis. The three drugs  
881 (*Terminalia arjuna*, *T. belerica* and *T. chebula*) were orally fed along with cholesterol to these rabbits. At the  
882 end of the experimental period, the plasma lipid profile and lipid peroxidation were assessed. Atherosclerotic  
883 lesions of the aorta were examined histologically. *T. arjuna* significantly inhibited rabbit atheroma formation.  
884 The results indicate that *T. arjuna* has significant hypolipidemic activity (Shaila et al., 1998).

### 885 44 h) *Ocimum sanctum*

886 *Ocimum sanctum* is commonly known as Tulsi.

887 In the present study, 1% Tulsi leaf powder was fed to normal and diabetic rats for a period of one month to  
888 explore the effect on fasting blood sugar, uric acid, total amino acids, and the lipid profile in serum and tissue  
889 lipids. The results indicated a significant reduction in fasting blood sugar, uric acid, total amino acids, TC, TG,  
890 phospholipids and total lipids. In liver, total cholesterol, triglyceride and total lipids were significantly lowered.  
891 Total lipids were significantly reduced in kidney. In heart, a significant fall in total cholesterol and phospholipids  
892 was observed. Study observations confirm the hypoglycemic and hypolipidemic effect of Tulsi in diabetic rats  
893 (Rai et al., 1997).

### 894 45 i) *Curcuma longa* and *Nardostachys jatamansi*

895 The hypolipidemic activity of *Curcuma longa* and *Nardostachys jatamansi* was studied in tritoninduced  
896 hyperlipidaemic rats. Oral feeding of fifty per cent ethanolic extract of *Curcuma longa* and *Nardostachys jatamans*  
897 resulted in elevation of HDLcholesterol/total cholesterol ratio. The extracts also caused a significant reduction  
898 in the ratio of total cholesterol/phospholipids. The cholesterol and triglyceride lowering activity of *Curcuma*  
899 *longa* was superior as compared to *N. jatamansi* in triton-induced hyperlipidaemic rats. It was concluded that  
900 *Curcuma longa* possesses significant hypolipidemic activity and has protective action against heart disease and  
901 atherogeneity (Dixit et al., 1988).

902 V.

## 903 46 Conclusion

904 The renewed interest in the search for new drugs from natural sources, especially from plant sources for the  
905 treatment of cardiovascular conditions, has gained global attention during the last two decades. Development of  
906 such indigenous herbal products with potential cardioprotective effects may be a boon in developing countries  
907 like India and South East Asian Nations as the synthetic drugs are comparatively costly and therefore patients  
908 belonging to weaker sections of the society may be non-complaint in therapy on long term basis. India is blessed  
909 with natural resources, primarily due to the rich biodiversity they harbor, which may be sources of new drugs  
910 with potential novel structures. However, of this rich biodiversity, only a small portion has been studied for  
911 its medicinal potential. Thus, a major opportunity exists in our natural resources for identifying and selecting  
912 efficacious, inexpensive and safer approaches for cardioprotection.

913 There is a paucity of scientific data on herbal medicines as few systemically designed studies on herbal medicines  
914 are currently available and their riskversus-benefit ratios are not clearly elucidated. These medicinal plants need  
915 to be investigated scientifically and rigorously to define their role in prevention and treatment of cardiovascular  
916 conditions and to stimulate future pharmaceutical development of therapeutically beneficial herbal drugs. At the  
917 same time, legal surveillance of herbal medicine use with low safety margins, adverse cardiovascular reactions  
918 and drug interactions should be instituted. <sup>1 2 3</sup>

---

<sup>1</sup>© 2012 Global Journals Inc. (US)

<sup>2</sup>© 2012 Global Journals Inc. (US) © 2012 Global Journals Inc. (US) The Beneficial Effects of Herbs in  
Cardiovascular Diseases

<sup>3</sup>© 2012 Global Journals Inc. (US) © 2012 Global Journals Inc. (US)

919 [Bensky et al. ()] , D Bensky , A Gamble , Usa . 1990. Chinese Herbal Medicine.

920 [ Arzneimittelforschung ()] , *Arzneimittelforschung* 1993.

921 [ Zhongguo Zhong Yao Za Zhi (2000)] , *Zhongguo Zhong Yao Za Zhi* 2000 May. 25 (5) p. .

922 [ Phytomedicine ()] , *Phytomedicine* 2004. 11 p. .

923 [ Mol Cell Biochem ()] , *Mol Cell Biochem* 2005. 275 p. .

924 [Yang et al. (2003)] 'A clinical study on manshuiling oral liquid in treating elder patients with congestive heart failure of type heart and kidney yang deficiency'. D Y Yang , X L Wu , H Xu , X Z Duan , S W Wang , Z Z Lu . *Zhongguo Zhong Yao Za Zhi* 2003 Nov. 28 (11) p. .

927 [Degenring et al. ()] 'A randomised double blind placebo controlled clinical trial of a standardized extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II'. F H Degenring , A Suter , M Weber , R Saller . *Phytomedicine* 2003. 10 (5) p. .

930 [Degenring et al. ()] 'A randomised double blind placebo controlled clinical trial of a standardized extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II'. F H Degenring , A Suter , M Weber , R Saller . *Phytomedicine* 2003. 10 (5) p. .

933 [Almeida et al. (2006)] 'Activity of Cecropia lyratiloba extract on contractility of cardiac and smooth muscles in Wistar rats'. Ramos Almeida , R , Montani Raimundo , J , Rodrigues Oliveira , R , Coelho Kaplan , M A Gattass , C R Sudo , R T Zapata-Sudo , G . *Clin Exp Pharmacol Physiol* 2006 Jan-Feb. 33 (1-2) p. .

936 [Xue et al. (2002)] 'Agathosma betulina. Depressive effect of total flavonoid fraction of Astragalus complanatus R. Brand its influence upon hemodynamics in SHR'. B Xue , J X Li , L B Chen . *Zhongguo Zhong Yao Za Zhi* 2002 Nov. 27 (11) p. .

939 [Geethan and Prince (2008)] 'Antihyperlipidemic effect of D-pinitol on streptozotocin-induced diabetic Wistar rats'. P K Geethan , P S Prince . *J Biochem Mol Toxicol* 2008 Jul-Aug. 22 (4) p. .

941 [Gibbons and Oriowo (2001)] 'Antihypertensive effect of an aqueous extract of Zygophyllum coccineum L. in rats'. S Gibbons , M A Oriowo . *Phytother Res* 2001 Aug. 15 (5) p. .

943 [Salas et al. (1987)] 'Antihypertensive effect of Cecropia obtusifolia (Moraceae) leaf extract on rats'. I Salas , J R Brenes , O M Morales . *Rev Biol Trop* 1987 Jun. 35 (1) p. .

945 [Rhiouani et al. (2001)] 'Antihypertensive effect of Herniaria glabra saponins in the spontaneously hypertensive rat'. H Rhiouani , B Lyoussi , A Settaf , Y Cherrah , M Hassar . *Ann Pharm Fr* 2001 May. 59 (3) p. .

947 [Zhou et al. (1999)] 'Antihypertensive study of xingnao qingxuan recipe'. Y Zhou , X Hu , Z Zhao , X He , Q Peng , X Peng , L Huang , B Sun , R Cao . *Zhongguo Zhong Yao Za Zhi* 1999 Aug. 24 (8) p. .

949 [Gharooni and Sarkarati ()] 'Application of Apium graveolens in treatment of hypertension'. M Gharooni , A R Sarkarati . *Tehran Univ Med J* 2000. 58 p. .

951 [Mamtani and Mamtani (2005)] 'Ayurveda and yoga in cardiovascular diseases'. R Mamtani , R Mamtani . *Cardiol Rev* 2005 May-Jun. 13 (3) p. . (Review)

953 [Mohanty et al. (2010)] 'Bacopa monniera protects rat heart against ischaemia-reperfusion injury: role of key apoptotic regulatory proteins and enzymes'. I R Mohanty , U Maheshwari , D Joseph , Y Deshmukh . *J Pharm Pharmacol* 2010 Sep. 62 (9) p. .

956 [Wu et al. (2007)] 'Beneficial effects of the extract from Corydalis yanhusuo in rats with heart failure following myocardial infarction'. L Wu , H Ling , L Li , L Jiang , M He . *J Pharm Pharmacol* 2007 May. 59 (5) p. .

958 [Eno et al. (2000)] 'Blood pressure depression by the fruit juice of Carica papaya (L.) in renal and DOCA-induced hypertension in the rat'. A E Eno , O I Owo , E H Itam , R S Konya . *Phytother Res* 2000 Jun. 14 (4) p. .

960 [Yamashiro et al. (2003)] 'Cardioprotective effects of extracts from Psidium guajava L and Limonium wrightii, Okinawan medicinal plants, against ischemia-reperfusion injury in perfused rat hearts'. S Yamashiro , K Noguchi , T Matsuzaki , K Miyagi , J Nakasone , M Sakanashi , M Sakanashi , I Kukita , Y Aniya , M Sakanashi . *Pharmacology* 2003 Mar. 67 (3) p. .

964 [Lau et al. ()] 'Cardiovascular actions of berberine'. C W Lau , X Q Yao , Z Y Chen , W H Ko , Y Huang . *Cardiovasc Drug Rev* 2001. 19 (3) p. . (Fall)

966 [Wong et al. (2000)] 'Cardiovascular actions of Radix Stephaniae Tetrandrae: a comparison with its main component, tetrandrine'. T M Wong , S Wu , X C Yu , H Y Li . *Acta Pharmacol Sin* 2000 Dec. 21 (12) p. .

969 [Ibarrola et al. ()] 'Chronic administration of aqueous extract of Hibiscus sabdariffa attenuates hypertension and reverses cardiac hypertrophy in 2K-1C hypertensive rats'. I P Ibarrola , R R Ettarh , S A Adigun . *J Ethnopharmacol* 2003. 86 p. .

972 [Brankovic et al. (2011)] 'Comparison of the hypotensive and bradycardic activity of ginkgo, garlic, and onion extracts'. S Brankovic , M Radenkovic , D Kitic , S Veljkovic , V Ivetic , D Pavlovic , B Miladinovic . *Clin Exp Hypertens* 2011. 2011 Jan 26. 33 (2) p. .

975 [Liebgott et al. (2000)] 'Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion'. T Liebgott , M Miollan , Y Berchadsky , K Drieu , M Culcasi , S Pietri . *Basic Res Cardiol* 2000 Oct. 95 (5) p. .

976

977

978 [Carini et al. (2003)] 'Complexation of Ginkgo biloba extract with phosphatidylcholine improves cardioprotective activity and increases the plasma antioxidant capacity in the rat'. M Carini , G Aldini , G Rossoni , P Morazzoni , R M Facino . *Basic Res Cardiol* 2003 Feb. 98 (1) p. .

981 [Ju (2005)] *Crataegus oxyacantha (aubepine) in the use as herb medicine in France. 8. Zhongguo Zhong Yao Za Zhi*, L Y Ju . 2005 Apr. 30 p. .

982

983 [Fahim et al. (1995)] 'Effect of Ajmaloon on the baroreceptor-heart rate reflex in anaesthetized rabbits and monkeys'. M Fahim , M S Khan , H A Hameed . *Indian J Physiol Pharmacol* 1995 Apr. 39 (2) p. .

984

985 [Sivakumar and Sivakumar ()] 'Effect of an indigenous herbal compound preparation 'Trikatu' on the lipid profiles of atherogenic diet and standard diet fed *Rattus norvegicus*'. V Sivakumar , S Sivakumar . *Phytother Res* 2004.

986

987

988 [Mohanty et al. (2006)] 'Effect of Curcuma longa and Ocimum sanctum on myocardial apoptosis in experimentally induced myocardial ischemic-reperfusion injury'. I Mohanty , D S Arya , S K Gupta . *BMC Complement Altern Med* 2006 Feb 19. 6 p. 3.

989

990

991 [Mohanty et al. (2006)] 'Effect of Curcuma longa and Ocimum sanctum on myocardial apoptosis in experimentally induced myocardial ischemic-reperfusion injury'. I Mohanty , D S Arya , S K Gupta . *BMC Complement Altern Med* 2006 Feb 19. 6 p. 3.

992

993

994 [Xing et al. (2007)] *Effect of Daming capsule on expression of connexin43 isoforms in hyperlipemic rat's cardiac muscle. 3. Zhongguo Zhong Yao Za Zhi*, Y Xing , P Yue , L H Sun , W X Zhao , Y Wang , Y Zhang , X Liu , Y J Lu , B F Yang . 2007 Jul. 32 p. .

995

996

997 [Qidwai et al. (2000)] 'Effect of dietary garlic (*Allium Sativum*) on the blood pressure in humans-a pilot study'. W Qidwai , R Qureshi , S N Hasan , S I Azam . *J Pak Med Assoc* 2000 Jun. 50 (6) p. .

998

999 [Bordia] *Effect of garlic on blood lipids in patients with coronary heart disease*, A Bordia .

1000 [Ried et al. ()] 'Effect of garlic on blood pressure: A systematic review and meta-analysis'. K Ried , O R Frank , N P Stocks , P Fakler , T Sullivan . *BMC Cardiovasc Disord* 2008. 8 p. 13.

1001

1002 [Han et al. ()] 'Effect of red ginseng on blood pressure in patients with essential hypertension and white coat hypertension'. K H Han , S C Choe , H S Kim , D W Sohn , K Y Nam , B H Oh , M M Lee , Y B Park , Y S Choi , J D Seo , Y W Lee . *Am J Chin Med* 1998. 26 (2) p. .

1003

1004

1005 [Liu et al. (2005)] 'Effect of Shenqi Fuzheng injection (SFI) on immune function in patients with congestive heart failure'. H Liu , X Wu , Y Zhang , W Lian . *Zhong Yao Cai* 2005 Sep. 28 (9) p. .

1006

1007 [Rai et al. ()] 'Effect of Tulasi (*Ocimum sanctum*) leaf powder supplementation on blood sugar levels, serum lipids and tissue lipids in diabetic rats'. V Rai , U Iyer , U V Mani . *Plant Foods Hum Nutr* 1997. 50 (1) p. .

1008

1009 [Hu and Hou ()] 'Effect of zhimu and huangqi on cardiac hypertrophy and response to stimulation in mice'. Y C Hu , J Y Hou . *Zhongguo Zhong Yao Za Zhi* 2003.

1010

1011 [Herrera-Arellano et al.] *Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: A controlled and randomized clinical trial*, A Herrera-Arellano , S Flores-Romero , M A Chávez-Soto , J Tortoriello .

1012

1013

1014 [Zhou et al.] *Effects of components isolated from Astragalus membranaceus Bunge on cardiac function injured by myocardial ischemia reperfusion in rats*, J Y Zhou , Y Fan , J L Kong , D Z Wu , Z B Hu .

1015

1016 [Shen et al. (1998)] 'Effects of EGb 761 on nitric oxide and oxygen free radicals, myocardial damage and arrhythmia in ischemia-reperfusion injury in vivo'. J Shen , J Wang , B Zhao , J Hou , T Gao , W Xin . *Biochim Biophys Acta* 1998 Apr 28. 1406 (3) p. .

1017

1018

1019 [Reinhart et al. ()] 'Effects of garlic on blood pressure in patients with and without systolic hypertension: A meta-analysis'. K M Reinhart , C I Coleman , C Teevan , P Vachhani , C M White . *Ann Pharmacother* 2008. 42 p. .

1020

1021

1022 [Guillon et al. (1986)] 'Effects of Ginkgo biloba extract on 2 models of experimental myocardial ischemia'. J M Guillon , L Rochette , J Baranes . *Presse Med* 1986 Sep 25. 15 (31) p. .

1023

1024 [Ding et al. (1995)] 'Effects of red ginseng on the congestive heart failure and its mechanism'. D Z Ding , T K Shen , Y Z Cui . *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1995 Jun. 15 (6) p. .

1025

1026 [Lai et al. (2004)] 'Effects of sasanquasaponin on ischemia and reperfusion injury in mouse hearts'. Z F Lai , Z Shao , Y Z Chen , M He , Q Huang , K Nishi . *J Pharmacol Sci* 2004 Mar. 94 (3) p. .

1027

1028 [Han et al. (2004)] 'Effects of shuangshen tongguan (SSTG) on TNF-alpha, ICAM-1 during myocardial ischemia-reperfusion injury'. X Han , J X Liu , X B Ma , Y H Wang . *Zhongguo Zhong Yao Za Zhi* 2004 Nov. 29 (11) p. .

1029

1030

1031 [Sandhu et al. (2010)] 'Effects of *Withania somnifera* (Ashwagandha) and *Terminalia arjuna* (Arjuna) on physical  
1032 performance and cardiorespiratory endurance in healthy young adults'. *J S Sandhu* , *B Shah* , *S Shenoy* , *S  
1033 Chauhan* , *G S Lavekar* , *M M Padhi* . *Int J Ayurveda Res* 2010 Jul. 1 (3) p. .

1034 [Shao et al. (1999)] 'Extract from *Scutellaria baicalensis* Georgi attenuates oxidant stress in cardiomyocytes'. *Z  
1035 H Shao* , *C Q Li* , *Vanden Hoek* , *T L Becker* , *L B Schumacker* , *P T Wu* , *J A Attele* , *A S Yuan* , *CS . J  
1036 Mol Cell Cardiol* 1999 Oct. 31 (10) p. .

1037 [Pedraza-Chaverri et al. (2000)] 'Garlic ameliorates hyperlipidemia in chronic aminonucleoside nephrosis'. *J  
1038 Pedraza-Chaverri* , *O N Medina-Campos* , *M A Granados-Silvestre* , *P D Maldonado* , *I M Olivares-Corichi  
1039 , R Hernández-Pando* . *Mol Cell Biochem* 2000 Aug. 211 (1-2) p. .

1040 [Fallon et al. (1998)] 'Garlic prevents hypoxic pulmonary hypertension in rats'. *M B Fallon* , *G A Abrams* , *T T  
1041 Abdel-Razek* , *J Dai* , *S J Chen* , *Y F Chen* , *B Luo* , *S Oparil* , *D D Ku* . *Am J Physiol* 1998 Aug. 275 (2)  
1042 p. . (Pt 1)

1043 [Dhawan and Jain] *Garlic supplementation prevents oxidative DNA damage in essential hypertension*, *V Dhawan  
1044 , S Jain* .

1045 [Umegaki et al. (2000)] 'Ginkgo biloba extract attenuates the development of hypertension in deoxycorticosterone acetate-salt hypertensive rats'. *K Umegaki* , *K Shinozuka* , *K Watarai* , *H Takenaka* , *M Yoshimura  
1046 , P Daohua* , *T Esashi* . *Clin Exp Pharmacol Physiol* 2000 Apr. 27 (4) p. .

1047 [Yoshikawa et al. ()] 'Ginkgo biloba leaf extract: review of biological actions and clinical applications'. *T  
1048 Yoshikawa* , *Y Naito* , *M Kondo* . *Antioxid Redox Signal* 1999. 1 (4) p. .

1049 [Stanely Mainzen Prince et al. (1999)] 'Hypolipidaemic action of *Tinospora cordifolia* roots in alloxan diabetic  
1050 rats'. *P Stanely Mainzen Prince* , *V P Menon* , *G Gunasekaran* . *J Ethnopharmacol* 1999 Jan. 64 (1) p. .

1051 [Dixit et al. (1988)] 'Hypolipidaemic effects of *Curcuma longa* L and *Nardostachys jatamansi*, DC in triton-  
1052 induced hyperlipidaemic rats'. *V P Dixit* , *P Jain* , *S C Joshi* . *Indian J Physiol Pharmacol* 1988 Oct-Dec. 32  
1053 (4) p. .

1054 [Shaila et al. (1998)] 'Hypolipidemic activity of three indigenous drugs in experimentally induced atherosclerosis'.  
1055 *H P Shaila* , *S L Udupa* , *A L Udupa* . *Int J Cardiol* 1998 Dec 1. 67 (2) p. .

1056 [Magos et al. (2008)] 'Hypotensive and vasorelaxant effects of the procyanidin fraction hypertensive rats'. *G A  
1057 Magos* , *J C Mateos* , *E Páez* , *G Fernández* , *C Lobato* , *C Márquez* , *R G Enríquez* . *J Ethnopharmacol*  
1058 2008 Apr 17. 2008 Jan 20. 117 (1) p. .

1059 [Osim et al. (1999)] 'Hypotensive effect of crude extract *Olea. africana* (Oleaceae) in normo and hypertensive  
1060 rats'. *E E Osim* , *E F Mbajorgu* , *G Mukarati* , *R F Vaz* , *B Makufa* , *O Munjeri* , *C T Musabayane* . *Cent  
1061 Afr J Med* 1999 Oct. 45 (10) p. .

1062 [Dimo et al. (1999)] *Hypotensive effects of a methanol extract of *Bidens pilosa* Linn on hypertensive rats*. *C R  
1063 Acad Sci III*, *T Dimo* , *T B Nguelefack* , *P Kamtchouing* , *E Dongo* , *A Rakotonirina* , *S V Rakotonirina* .  
1064 1999 Apr. 322 p. .

1065 [Endo et al. ()] 'Hypotensive principles of *uncaria hookeri*'. *K Endo* , *Y Oshima* , *H Kikuchi* , *Y Koshihara* , *H  
1066 Hikino* . *Planta Med* 1983. 49 p. .

1067 [Chatterjee et al. (1997)] 'In vitro and in vivo studies on the cardioprotective action of oligomeric procyandins  
1068 in a *Crataegus* extract of leaves and blooms'. *S S Chatterjee* , *E Koch* , *H Jaggy* , *T Krzeminski* .  
1069 *Arzneimittelforschung* 1997 Jul. 47 (7) p. .

1070 [Ibarrola et al. ()] 'Isolation of hypotensive compounds from *Solanum sisymbriifolium* Lam'. *D A Ibarrola* , *Y  
1071 Montalbetti* , *O Heinichen* , *N Alvarenga* , *A Figueiredo* , *E A Ferro* . *J Ethnopharmacol* 2000. 70 p. .

1072 [Han et al. (2005)] 'Korea red ginseng water extract increases nitric oxide concentrations in exhaled breath'. *K  
1073 Han* , *I C Shin* , *K J Choi* , *Y P Yun* , *J T Hong* , *K W Oh* . *Nitric Oxide* 2005 May. 12 (3) p. .

1074 [Inoue et al. (1999)] 'Lipoprotein lipase activation by red ginseng saponins in hyperlipidemia model animals'. *M  
1075 Inoue* , *C Z Wu* , *D Q Dou* , *Y J Chen* , *Y Ogihara* . *Phytomedicine* 1999 Oct. 6 (4) p. .

1076 [Jerie ()] *Milestones of cardiovascular therapy: IV, Reserpine*. *Cas Lak Cesk*, *P Jerie* . 2007. 146 p. .

1077 [Schüssler and Fricke ()] *Myocardial effects of flavonoids from Crataegus species*. *Arzneimittelforschung*, *M  
1078 Schüssler* , *J Fricke* , *U* . 1995. 45 p. .

1079 [Schüssler et al. ()] *Myocardial effects of flavonoids from Crataegus species*. *Arzneimittelforschung*, *M Schüssler  
1080 , J Hlzl* , *U Fricke* . 1995. 45 p. .

1081 [Yim et al. (2000)] 'Myocardial protection against ischaemareperfusion injury by a *Polygonum multiflorum*  
1082 extract supplemented 'Dang-Gui decoction for enriching blood', a compound formulation, ex vivo'. *T K  
1083 Yim* , *W K Wu* , *W F Pak* , *D H Mak* , *S M Liang* , *K M Ko* . *Phytother Res* 2000 May. 14 (3) p. .

1084 [Makdassi et al. (1996)] 'Myocardial protection by pretreatment with *Crataegus oxyacantha*: an assessment by  
1085 means of the release of lactate dehydrogenase by the ischemic and reperfused Langendorff heart'. *Al Makdassi  
1086 , S Sweidan* , *H Müllner* , *S Jacob* , *R* . *Arzneimittelforschung* 1996 Jan. 46 (1) p. .

1087

## 46 CONCLUSION

---

1088 [Chan et al. ()] 'Myocardial protective effect of trilinolein: an antioxidant isolated from the medicinal plant  
1089 Panax pseudoginseng'. P Chan , C Y Hong , B Tomlinson , N C Chang , J P Chen , S T Lee , J T Cheng .  
1090 *Life Sci* 1997. 61 (20) p. .

1091 [Locket ()] 'Oral preparations of Rauwolfia Serpentina in treatment of essential hypertension'. S Locket . *British  
1092 Medical Journal* 1955. p. .

1093 [Facino et al. (1999)] 'Panax ginseng administration in the rat prevents myocardial ischemia-reperfusion damage  
1094 induced by hyperbaric oxygen: evidence for an antioxidant intervention'. Maffei Facino , R Carini , M Aldini  
1095 , G Berti , F Rossoni , G . *Planta Med* 1999 Oct. 65 (7) p. .

1096 [Magos et al. (1999)] 'Pharmacology of Casimiroa edulis IV. Hypotensive effects of compounds isolated from  
1097 methanolic extracts in rats and guinea pigs'. G A Magos , H Vidrio , W F Reynolds , R G Enríquez . *J  
1098 Ethnopharmacol* 1999 Jan. 64 (1) p. .

1099 [Tigno et al. ()] 'Phytochemical analysis and hemodynamic actions of Artemisia vulgaris L'. X T Tigno , F De  
1100 Guzman , A M Flora . *Clin Hemorheol Microcirc* 2000. 23 (2-4) p. .

1101 [Zhou et al. ()] 'Protection effect of Wenxin Keli on isoproterenol induced heart failure in rats'. F Zhou , S J Hu  
1102 , Y Mu . *Zhongguo Zhong Yao Za Zhi* 2007.

1103 [Sui et al. (2004)] 'Protective effect of ASS on myocardial ischemia-reperfusion injury in rats'. D Y Sui , S C Qu  
1104 , X F Yu , Y P Chen , X Y Ma . *Zhongguo Zhong Yao Za Zhi* 2004 Jan. 29 (1) p. .

1105 [Nasa et al.] *Protective effect of crataegus extract on the cardiac mechanical dysfunction in isolated perfused  
1106 working rat heart*, Y Nasa , H Hashizume , A N Hoque , Y Abiko .

1107 [Cheng and Liu (2005)] 'Protective effect of curcumin on myocardial ischemia reperfusion injury in Rats'. H  
1108 Cheng , W Liu , AiX . *Zhong Yao Cai* 2005 Oct. 28 (10) p. .

1109 [Gao et al. (2005)] 'Protective effect of the pretreatment with Chuanxiongphthalide A on the vascular endothelial  
1110 cells impaired by the ischemia and reperfusion in isolated rats hearts'. W Gao , R X Liang , Y Q Xiao , H J  
1111 Yang . *Zhongguo Zhong Yao Za Zhi* 2005 Sep. 30 (18) p. .

1112 [Mohanty et al. (2004)] 'Protective effects of Curcuma longa on ischemia-reperfusion induced myocardial injuries  
1113 and their mechanisms'. I Mohanty , D Singh Arya , A Dinda , S Joshi , K K Talwar , S K Gupta . *Life Sci*  
1114 2004 Aug 20. 75 (14) p. .

1115 [Han et al. (2009)] 'Protective effects of purified safflower extract on myocardial ischemia in vivo and in vitro'.  
1116 S Y Han , H X Li , X Ma , K Zhang , Z Z Ma , P F Tu . *Phytomedicine* 2009 Aug. 2009 Apr 24. 16 (8) p. .

1117 [Zhao et al. (2009)] 'Protective effects of sini decoction on adriamycininduced heart failure and its mechanism'.  
1118 M Q Zhao , W K Wu , D Y Zhao , X F Duan , Y Liu . *Zhong Yao Cai* 2009 Dec. 32 (12) p. .

1119 [Mulrow et al. (1984)] 'Reevaluation of digitalis efficacy'. C D Mulrow , J R Feussner , R Velez . *Ann Intern Med*  
1120 1984 Jul. 101 (1) p. . (New light on an old leaf)

1121 [Bharani et al. ()] 'Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure'. A Bharani  
1122 , A Ganguly , K D Bhargava . *Int J Cardiol* 1995.

1123 [Zhao et al. (2008)] 'Study on activity and mechanism of Sini Decoction anti-mitochondrial oxidation injury  
1124 caused by myocardial ischemia/reperfusion'. D Y Zhao , M Q Zhao , W K Wu . *Zhong Yao Cai* 2008 Nov. 31  
1125 (11) p. .

1126 [Kou et al. (2008)] 'The antioxidative effect of Sanwei Tanxiang powder on rats' hearts against myocardial  
1127 ischemia and reperfusion injury'. Y Y Kou , X D Zha , Y F Li , R L Ge . *Zhong Yao Cai* 2008 Jul. 31  
1128 (7) p. .

1129 [Tom et al. (2010)] 'The aqueous extract of Terminalia superba (Combretaceae) prevents glucose-induced  
1130 hypertension in rats'. E N Tom , C Demougeot , O B Mtopi , T Dimo , P D Djomeni , D C Bilanda ,  
1131 C Girard , A Berthelot . *J Ethnopharmacol* 2011 Jan 27. 2010 Nov 11. 133 (2) p. .

1132 [Krikler (1985)] 'The old woman from Shropshire" and William Withering'. D M Krikler . *J Am Coll Cardiol*  
1133 1985 May. 5 (5) p. . (The foxglove. Suppl A)

1134 [Yang et al. ()] 'The protective effect of habitual tea consumption on hypertension'. Y C Yang , F H Lu , J S  
1135 Wu , C H Wu , C J Chang . *Arch Intern Med* 2004. 164 p. .

1136 [Demers et al. (1999)] *The role of digitalis in the treatment of heart failure. 14. Coron Artery Dis*, C Demers ,  
1137 R S Mckelvie , S Yusuf . 1999 Sep. 10 p. .

1138 [Wray et al. ()] 'Two hundred years of the foxglove'. S Wray , D A Eisner , D G Allen . *Med Hist Suppl* 1985.  
1139 (5) p. .

1140 [Mohanty et al. (2008)] 'Withania somnifera provides cardioprotection and attenuates ischemiareperfusion in-  
1141 duced apoptosis'. I R Mohanty , D S Arya , S K Gupta . *Clin Nutr* 2008 Aug. 2008 Jul 11. 27 (4) p. .

1142 [Nicoll et al. ()] 'Zingiber officinale Roscoe): A hot remedy for cardiovascular disease?'. R Nicoll , M Y Henein ,  
1143 Ginger . *Int J Cardiol* 2009. 131 p. .